TPB 10-Q
Turning Point Brands, Inc. (TPB)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
(Mark One)
| | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended
or
| | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from _______________ to _______________
Commission file number:
TURNING POINT BRANDS, INC.
(Exact name of registrant as specified in its charter)
| | |
| (State or other jurisdiction of Incorporation or organization) | (I.R.S. Employer Identification No.) |
| | |
| (Address of principal executive offices) | (Zip Code) |
(
(Registrant’s telephone number, including area code)
Former name, former address and former fiscal year, if changed since last report: not applicable
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| | | |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| | ☑ | Accelerated filer | ☐ | |
| Non-accelerated filer | ☐ | Smaller reporting company | | |
| Emerging growth company | |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes
At July 28, 2026, there were
TURNING POINT BRANDS, INC.
| Page No. |
|||
| PART I—FINANCIAL INFORMATION |
|||
| ITEM 1 |
Financial Statements (Unaudited) |
||
| Consolidated Balance Sheets as of June 30, 2026, and December 31, 2025 |
|||
| Consolidated Statements of Income for the three and six months ended June 30, 2026 and 2025 |
|||
| Consolidated Statements of Cash Flows for the six months ended June 30, 2026 and 2025 |
|||
| Consolidated Statements of Changes in Stockholders’ Equity for the six months ended June 30, 2026 and 2025 | 10 | ||
| ITEM 2 |
Management’s Discussion and Analysis of Financial Condition and Results of Operations |
||
| ITEM 3 |
|||
| ITEM 4 |
|||
| PART II—OTHER INFORMATION |
|||
| ITEM 1 |
|||
| ITEM 1A |
|||
| ITEM 2 |
|||
| ITEM 3 |
|||
| ITEM 4 |
|||
| ITEM 5 |
|||
| ITEM 6 |
|||
Cautionary Note Regarding Forward-Looking Statements
This Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 (this “Quarterly Report”), contains forward-looking statements within the meaning of the federal securities laws. Forward-looking statements may generally be identified by the use of words such as “anticipate,” “believe,” “expect,” “intend,” “plan,” and “will” or, in each case, their negative, or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. By their nature, forward-looking statements involve risks and uncertainties because they relate to events, and depend on circumstances, that may or may not occur in the future. As a result, actual events may differ materially from those expressed in, or suggested by, the forward-looking statements. Any forward-looking statement made by Turning Point Brands, Inc. (“TPB”), in this Quarterly Report on Form 10-Q speaks only as of the date hereof. New risks and uncertainties come up from time to time, and it is impossible for TPB to predict these events or how they may affect it. TPB has no obligation, and does not intend, to update any forward-looking statements after the date hereof, except as required by federal securities laws. Factors that could cause these differences include, but are not limited to:
| ● |
declining sales of tobacco products, and expected continuing decline of sales in the tobacco industry overall; |
| ● |
our dependence on a small number of third-party suppliers and producers; |
| ● |
the possibility that we will be unable to identify or contract with new suppliers or producers in the event of a supply or product disruption, as well as other supply chain concerns, including delays in product shipments and increases in freight cost; |
| ● |
the possibility that our licenses to use certain brands or trademarks will be terminated, challenged or restricted; |
| ● |
failure to maintain consumer brand recognition and loyalty of our customers and in anticipating and responding to changes in consumer preferences and purchase behavior; |
| ● |
our reliance on relationships with several large retailers and national chains for distribution of our products; |
| ● |
intense competition and our ability to compete effectively; |
| ● |
competition from illicit sources and the damage caused by illicit products to our brand equity; |
| ● |
contamination of our tobacco supply or products; |
| ● |
uncertainty and continued evolution of the markets for our products; |
| ● | recalls of our products; |
|
| ● | difficulties or liabilities arising from investments in businesses; |
| ● |
substantial and increasing regulation and changes in U.S. Food and Drug Administration (“FDA”) enforcement priorities; |
| ● |
regulation or marketing denials of our products by the FDA, which has broad regulatory powers; |
| ● |
many of our products contain nicotine, which is considered to be a highly addictive substance; |
| ● |
requirement to maintain compliance with master settlement agreement escrow account; |
| ● |
possible significant increases in federal, state and local municipal tobacco- and nicotine-related taxes; |
| ● |
our products are marketed pursuant to a policy of FDA enforcement priorities which could change, and our products could become subject to increased regulatory burdens by the FDA; |
| ● |
sensitivity of end-customers to increased sales taxes and economic conditions, including as a result of inflation and other declines in purchasing power; |
| ● |
possible increasing international control and regulation; |
| ● |
failure to comply with environmental, health and safety regulations; |
| ● |
imposition of significant tariffs on imports into the U.S.; |
|
| ● |
the scientific community’s lack of information regarding the long-term health effects of certain substances contained in some of our products; |
| ● |
significant product liability litigation; |
| ● |
our amount of indebtedness; |
|
| ● | our credit rating and ability to access well-functioning capital markets; |
| ● |
the terms of our indebtedness, which may restrict our current and future operations; |
| ● |
our ability to establish and maintain effective internal controls over financial reporting; |
| ● |
our certificate of incorporation and bylaws, as well as Delaware law and certain regulations, could discourage or prohibit acquisition bids or merger proposals, which may adversely affect the market price of our common stock; |
| ● |
our certificate of incorporation limits the ownership of our common stock by individuals and entities that are Restricted Investors (as defined in our Certificate of Incorporation). These restrictions may affect the liquidity of our common stock and may result in Restricted Investors being required to sell or redeem their shares at a loss or relinquish their voting, dividend and distribution rights; |
| ● |
future sales of our common stock in the public market could reduce our stock price, and any additional capital raised by us through the sale of equity or convertible securities may dilute your ownership in us; |
| ● |
we may issue preferred stock whose terms could adversely affect the voting power or value of our common stock; |
| ● |
our business may be damaged by events outside of our or our suppliers’ control, such as the impact of epidemics or pandemics, political upheavals, or natural disasters; |
| ● |
adverse impact of climate change and legal and regulatory requirements related to climate change and environmental sustainability; |
| ● |
our reliance on information technology; |
| ● |
cybersecurity and privacy breaches, including due to artificial intelligence; |
| ● |
failure to manage our growth; |
| ● |
failure to successfully identify, negotiate and complete suitable acquisition opportunities, integrate our acquisitions or otherwise be unable to benefit from pursuing acquisitions; |
| ● |
fluctuations in our results; |
| ● |
exchange rate fluctuations; |
| ● |
adverse U.S. and global economic conditions; |
| ● |
departure of key management personnel or our inability to attract and retain talent; |
| ● |
infringement on or misappropriation of our intellectual property; |
| ● |
third-party claims that we infringe on their intellectual property; and |
| ● |
impairment of intangible assets, including trademarks and goodwill. |
PART I—FINANCIAL INFORMATION
Item 1. Financial Statements
Consolidated Balance Sheets
(dollars in thousands except share data)
| (unaudited) | ||||||||
| June 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash | $ | $ | ||||||
| Accounts receivable, net of allowances of $ in 2026 and $ in 2025 | ||||||||
| Inventories, net | ||||||||
| Other current assets | ||||||||
| Total current assets | ||||||||
| Property, plant, and equipment, net | ||||||||
| Right of use assets | ||||||||
| Deferred financing costs, net | ||||||||
| Goodwill | ||||||||
| Other intangible assets, net | ||||||||
| Master Settlement Agreement (MSA) escrow deposits | ||||||||
| Other assets | ||||||||
| Total assets | $ | $ | ||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | $ | ||||||
| Accrued liabilities | ||||||||
| Total current liabilities | ||||||||
| Deferred tax liabilities, net | ||||||||
| Notes payable and long-term debt | ||||||||
| Other long-term liabilities | ||||||||
| Lease liabilities | ||||||||
| Total liabilities | $ | $ | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ equity: | ||||||||
| Preferred stock, $ par value; authorized shares ; issued and outstanding shares -- | ||||||||
| Common stock, voting, $ par value; authorized shares, ; issued shares and outstanding shares at June 30, 2026, and issued shares and outstanding shares at December 31, 2025 | ||||||||
| Common stock, nonvoting, $ par value; authorized shares, ; issued and outstanding shares -- | ||||||||
| Additional paid-in capital | ||||||||
| Cost of repurchased common stock ( shares at June 30, 2026 and shares at December 31, 2025) | ( | ) | ( | ) | ||||
| Accumulated other comprehensive loss | ( | ) | ( | ) | ||||
| Accumulated earnings | ||||||||
| Non-controlling interest | ||||||||
| Total stockholders’ equity | ||||||||
| Total liabilities and stockholders’ equity | $ | $ | ||||||
The accompanying notes are an integral part of the consolidated financial statements.
Consolidated Statements of Income
(dollars in thousands except share and per share data)
(unaudited)
| Three Months Ended | Six Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Net sales | $ | $ | $ | $ | ||||||||||||
| Cost of sales | ||||||||||||||||
| Gross profit | ||||||||||||||||
| Selling, general, and administrative expenses | ||||||||||||||||
| Operating income | ||||||||||||||||
| Other expense, net | ||||||||||||||||
| Interest expense, net | ||||||||||||||||
| Investment loss (gain) | ( | ) | ( | ) | ||||||||||||
| (Income) loss from equity method investment | ( | ) | ( | ) | ||||||||||||
| Loss on extinguishment of debt | ||||||||||||||||
| Income before income taxes | ||||||||||||||||
| Income tax expense | ||||||||||||||||
| Consolidated net income | ||||||||||||||||
| Net income attributable to non-controlling interest | ||||||||||||||||
| Net income attributable to Turning Point Brands, Inc. | $ | $ | $ | $ | ||||||||||||
| Basic income per common share: | ||||||||||||||||
| Net income attributable to Turning Point Brands, Inc. | $ | $ | $ | $ | ||||||||||||
| Diluted income per common share: | ||||||||||||||||
| Net income attributable to Turning Point Brands, Inc. | $ | $ | $ | $ | ||||||||||||
| Weighted average common shares outstanding: | ||||||||||||||||
| Basic | ||||||||||||||||
| Diluted | ||||||||||||||||
The accompanying notes are an integral part of the consolidated financial statements.
Consolidated Statements of Comprehensive Income
(dollars in thousands)
(unaudited)
| Three Months Ended | ||||||||
| June 30, | ||||||||
| 2026 | 2025 | |||||||
| Consolidated net income | $ | $ | ||||||
| Other comprehensive income (loss), net of tax | ||||||||
| Unrealized (loss) gain on MSA investments, net of tax of $ in 2026 and $ in 2025 | ( | ) | ||||||
| Foreign currency translation, net of tax of $ in 2026 and 2025 | ( | ) | ||||||
| Unrealized gain on investments, net of tax of $ in 2026 and $ in 2025 | ||||||||
| Consolidated comprehensive income | ||||||||
| Comprehensive income attributable to non-controlling interest | ||||||||
| Comprehensive income attributable to Turning Point Brands, Inc. | $ | $ | ||||||
| Six Months Ended | ||||||||
| June 30, | ||||||||
| 2026 | 2025 | |||||||
| Consolidated net income | $ | $ | ||||||
| Other comprehensive income (loss), net of tax | ||||||||
| Unrealized (loss) gain on MSA investments, net of tax of $ in 2026 and $ in 2025 | ( | ) | ||||||
| Foreign currency translation, net of tax of $ in 2026 and 2025 | ( | ) | ||||||
| Unrealized gain on derivative instruments, net of tax of $ in 2026 and $ in 2025 | ||||||||
| Unrealized gain on investments, net of tax of $ in 2026 and $30 in 2025 | ||||||||
| ( | ) | |||||||
| Consolidated comprehensive income | ||||||||
| Comprehensive income attributable to non-controlling interest | ||||||||
| Comprehensive income attributable to Turning Point Brands, Inc. | $ | $ | ||||||
The accompanying notes are an integral part of the consolidated financial statements.
Consolidated Statements of Cash Flows
(dollars in thousands)
(unaudited)
| Six Months Ended | ||||||||
| June 30, | ||||||||
| 2026 | 2025 | |||||||
| Cash flows from operating activities: | ||||||||
| Consolidated net income | $ | $ | ||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
| Loss on extinguishment of debt | ||||||||
| Loss on sale of property, plant, and equipment | ||||||||
| (Income) loss from equity method investment | ( | ) | ||||||
| Loss (gain) on investments, net | ( | ) | ||||||
| Depreciation and other amortization expense | ||||||||
| Amortization of other intangible assets | ||||||||
| Amortization of deferred financing costs | ||||||||
| Deferred income tax expense | ( | ) | ||||||
| Stock compensation expense | ||||||||
| Noncash lease income | ( | ) | ( | ) | ||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | ( | ) | ||||||
| Inventories | ( | ) | ( | ) | ||||
| Other current assets | ( | ) | ( | ) | ||||
| Other assets | ( | ) | ( | ) | ||||
| Accounts payable | ||||||||
| Accrued liabilities and other | ( | ) | ||||||
| Net cash provided by operating activities | $ | $ | ||||||
| Cash flows from investing activities: | ||||||||
| Capital expenditures | $ | ( | ) | $ | ( | ) | ||
| Payment for equity investments | ( | ) | ( | ) | ||||
| Purchases of investments | ( | ) | ( | ) | ||||
| Proceeds from sale of investments | ||||||||
| MSA escrow deposits, net | ( | ) | ||||||
| Purchase of option agreement | ( | ) | ||||||
| Net cash used in investing activities | $ | ( | ) | $ | ( | ) | ||
| Cash flows from financing activities: | ||||||||
| Redemption of 2026 Notes | $ | $ | ( | ) | ||||
| Proceeds from 2032 Notes | ||||||||
| Equity offering proceeds | ||||||||
| Tax distribution | ( | ) | ||||||
| Payment of dividends | ( | ) | ( | ) | ||||
| Payment of financing costs | ( | ) | ||||||
| Exercise of options | ||||||||
| Redemption of options | ( | ) | ||||||
| Redemption of restricted stock units | ( | ) | ( | ) | ||||
| Redemption of performance based restricted stock units | ( | ) | ( | ) | ||||
| Net cash provided by financing activities | $ | $ | ||||||
| Net increase in cash | $ | $ | ||||||
| Effect of foreign currency translation on cash | $ | $ | ||||||
| Cash, beginning of period: | ||||||||
| Unrestricted | $ | $ | ||||||
| Restricted | ||||||||
| Total cash at beginning of period | $ | $ | ||||||
| Cash, end of period: | ||||||||
| Unrestricted | $ | $ | ||||||
| Restricted | ||||||||
| Total cash at end of period | $ | $ | ||||||
| Supplemental schedule of noncash investing activities: | ||||||||
| Accrued capital expenditures | $ | $ | ||||||
| Investment acquired in exchange for net assets held for sale | $ | $ | ||||||
| Supplemental schedule of noncash financing activities: | ||||||||
| Dividends declared not paid | $ | $ | ||||||
The accompanying notes are an integral part of the consolidated financial statements
Consolidated Statements of Changes in Stockholders’ Equity
For the Three Months Ended June 30, 2026 and 2025
(dollars in thousands except share data)
(unaudited)
| Cost of | Accumulated | |||||||||||||||||||||||||||||||
| Common | Additional | Repurchased | Other | Non- | ||||||||||||||||||||||||||||
| Voting | Stock, | Paid-In | Common | Comprehensive | Accumulated | Controlling | ||||||||||||||||||||||||||
| Shares | Voting | Capital | Stock | Income (Loss) | Earnings | Interest | Total | |||||||||||||||||||||||||
| Beginning balance April 1, 2026 | $ | $ | $ | ( | ) | $ | ( | ) | $ | $ | $ | |||||||||||||||||||||
| Unrealized gain (loss) on MSA investments, net of tax of $ | - | ( | ) | ( | ) | |||||||||||||||||||||||||||
| Foreign currency translation, net of tax of $ | - | ( | ) | ( | ) | ( | ) | |||||||||||||||||||||||||
| Unrealized gain on investments, net of tax of $ | - | |||||||||||||||||||||||||||||||
| Stock compensation expense | - | |||||||||||||||||||||||||||||||
| Exercise of options | ||||||||||||||||||||||||||||||||
| Issuance of performance based restricted stock units | ||||||||||||||||||||||||||||||||
| Redemption of performance based restricted stock units | ||||||||||||||||||||||||||||||||
| Issuance of restricted stock units | ||||||||||||||||||||||||||||||||
| Redemption of restricted stock units | ||||||||||||||||||||||||||||||||
| Issuance of common stock in connection with equity offering, net of fees | ||||||||||||||||||||||||||||||||
| Tax distribution | - | ( | ) | ( | ) | |||||||||||||||||||||||||||
| Dividends | - | ( | ) | ( | ) | |||||||||||||||||||||||||||
| Net income | - | |||||||||||||||||||||||||||||||
| Ending balance June 30, 2026 | $ | $ | $ | ( | ) | $ | ( | ) | $ | $ | $ | |||||||||||||||||||||
| Beginning balance April 1, 2025 | $ | $ | $ | ( | ) | $ | ( | ) | $ | $ | $ | |||||||||||||||||||||
| Unrealized gain on MSA investments, net of tax of $ | - | |||||||||||||||||||||||||||||||
| Foreign currency translation, net of tax of $ | - | |||||||||||||||||||||||||||||||
| Unrealized gain on investments, net of tax of $ | - | |||||||||||||||||||||||||||||||
| Stock compensation expense | - | |||||||||||||||||||||||||||||||
| Exercise of options | ||||||||||||||||||||||||||||||||
| Issuance of performance based restricted stock units | ( | ) | ||||||||||||||||||||||||||||||
| Redemption of performance based restricted stock units | ||||||||||||||||||||||||||||||||
| Issuance of restricted stock units | ||||||||||||||||||||||||||||||||
| Redemption of restricted stock units | ( | ) | ( | ) | ||||||||||||||||||||||||||||
| Dividends | - | ( | ) | ( | ) | |||||||||||||||||||||||||||
| Net income | - | |||||||||||||||||||||||||||||||
| Ending balance June 30, 2025 | $ | $ | $ | ( | ) | $ | ( | ) | $ | $ | $ | |||||||||||||||||||||
The accompanying notes are an integral part of the consolidated financial statements.
Consolidated Statements of Changes in Stockholders’ Equity
For the Six Months Ended June 30, 2026 and 2025
(dollars in thousands except share data)
(unaudited)
| Cost of | Accumulated | |||||||||||||||||||||||||||||||
| Common | Additional | Repurchased | Other | Non- | ||||||||||||||||||||||||||||
| Voting | Stock, | Paid-In | Common | Comprehensive | Accumulated | Controlling | ||||||||||||||||||||||||||
| Shares | Voting | Capital | Stock | Income (Loss) | Earnings | Interest | Total | |||||||||||||||||||||||||
| Beginning balance January 1, 2026 | $ | $ | $ | ( | ) | $ | ( | ) | $ | $ | $ | |||||||||||||||||||||
| Unrealized gain on MSA investments, net of tax of $ | - | ( | ) | ( | ) | |||||||||||||||||||||||||||
| Foreign currency translation, net of tax of $ | - | ( | ) | ( | ) | ( | ) | |||||||||||||||||||||||||
| Unrealized loss on investments, net of tax of $ | - | |||||||||||||||||||||||||||||||
| Stock compensation expense | - | |||||||||||||||||||||||||||||||
| Exercise of options | ||||||||||||||||||||||||||||||||
| Redemption of options | ||||||||||||||||||||||||||||||||
| Issuance of performance based restricted stock units | ||||||||||||||||||||||||||||||||
| Redemption of performance based restricted stock units | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||
| Issuance of restricted stock units | ||||||||||||||||||||||||||||||||
| Redemption of restricted stock units | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||
| Issuance of common stock in connection with equity offering, net of fees | ||||||||||||||||||||||||||||||||
| Tax distribution | - | ( | ) | ( | ) | |||||||||||||||||||||||||||
| Dividends | - | ( | ) | ( | ) | |||||||||||||||||||||||||||
| Net income | - | |||||||||||||||||||||||||||||||
| Ending balance June 30, 2026 | $ | $ | $ | ( | ) | $ | ( | ) | $ | $ | $ | |||||||||||||||||||||
| Beginning balance January 1, 2025 | $ | $ | $ | ( | ) | $ | ( | ) | $ | $ | $ | |||||||||||||||||||||
| Unrealized gain on MSA investments, net of tax of $ | - | |||||||||||||||||||||||||||||||
| Foreign currency translation, net of tax of $ | - | ( | ) | |||||||||||||||||||||||||||||
| Unrealized loss on derivative instruments, net of tax of $ | - | |||||||||||||||||||||||||||||||
| Unrealized gain on investments, net of tax of $ | - | |||||||||||||||||||||||||||||||
| Stock compensation expense | - | |||||||||||||||||||||||||||||||
| Exercise of options | ||||||||||||||||||||||||||||||||
| Redemption of options | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||
| Issuance of performance based restricted stock units | ( | ) | ( | ) | ||||||||||||||||||||||||||||
| Redemption of performance based restricted stock units | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||
| Issuance of restricted stock units | ||||||||||||||||||||||||||||||||
| Redemption of restricted stock units | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||
| Dividends | - | ( | ) | ( | ) | |||||||||||||||||||||||||||
| Net income | - | |||||||||||||||||||||||||||||||
| Ending balance June 30, 2025 | $ | $ | $ | ( | ) | $ | ( | ) | $ | $ | $ | |||||||||||||||||||||
The accompanying notes are an integral part of the consolidated financial statements.
Notes to Consolidated Financial Statements (Unaudited)
(dollars in thousands, except where designated and per share data)
Note 1. Business and Basis of Presentation
Description of Business
Turning Point Brands, Inc., including its subsidiaries (collectively referred to herein as the “Company,” “we,” “our,” or “us”), is a leading manufacturer, marketer and distributor of branded consumer products. The Company sells a wide range of products to adult consumers consisting of staple products with its iconic brands Zig-Zag® and Stoker’s® and its next generation products to fulfill evolving consumer preferences. The Company's segments are led by its core proprietary and iconic brands: Zig-Zag® and Stoker’s®, FRE® and ALP®. The Company’s products are available in more than
Basis of Presentation
The accompanying unaudited, interim, consolidated financial statements have been prepared in accordance with the accounting practices described in the Company’s audited, consolidated financial statements as of and for the year ended December 31, 2025. In the opinion of management, the unaudited, interim, consolidated financial statements included herein contain all adjustments necessary to present fairly the financial position, results of operations, and cash flows of the Company for the periods presented. Such adjustments, other than nonrecurring adjustments separately disclosed, are of a normal and recurring nature. The operating results for interim periods are not necessarily indicative of results to be expected for a full year or future interim periods. The unaudited, interim, consolidated financial statements should be read in conjunction with the Company’s audited, consolidated financial statements and accompanying notes as of and for the year ended December 31, 2025. The accompanying interim, consolidated financial statements are presented in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) and, accordingly, do not include all the disclosures required by generally accepted accounting principles in the United States (“GAAP”) with respect to annual financial statements.
Certain prior year amounts have been reclassified to conform to the current year’s presentation. The changes did not have an impact on the Company’s consolidated financial position, results of operations, or cash flows in any of the periods presented.
Tariff Refunds
On March 4, 2026, the U.S. Court of International Trade issued an additional ruling that importers that paid tariffs under the International Emergency Economic Powers Act ("IEEPA") are due refunds and ordered U.S. Customs and Border Protection ("CBP") to begin the refund process. Consistent with ASC 450-30 Gain contingencies, the Company does not recognize a tariff refund until the gain is realized or realizable – generally upon receipt of funds. The Company paid IEEPA tariffs totaling $
Note 2. Summary of Significant Accounting Policies
Consolidation
The consolidated financial statements include the accounts of the Company, its subsidiaries, all of which are wholly-owned, and variable interest entities (“VIEs”) for which the Company is considered to have a controlling interest based on the voting interest entity model or the variable interest entity model. All significant intercompany transactions have been eliminated.
U.S. GAAP requires the Company to identify entities for which control is achieved through means other than voting rights and to determine whether the Company is the primary beneficiary of VIEs. A VIE is broadly defined as an entity with one or more of the following characteristics: (a) the total equity investment at risk is insufficient to finance the entity’s activities without additional subordinated financial support; (b) as a group, the holders of the equity investment at risk lack (i) the ability to make decisions about the entity’s activities through voting or similar rights, (ii) the obligation to absorb the expected losses of the entity, or (iii) the right to receive the expected residual returns of the entity; and (c) the equity investors have voting rights that are not proportional to their economic interests, and substantially all of the entity’s activities either involve, or are conducted on behalf of, an investor that has disproportionately few voting rights. The Company consolidates its investment in a VIE when it determines that it is the VIE’s primary beneficiary. The Company may change its original assessment of a VIE upon subsequent events such as the modification of contractual arrangements that affects the characteristics or adequacy of the entity’s equity investments at risk and the disposition of all or a portion of an interest held by the primary beneficiary.
The primary beneficiary of a VIE is the entity that has both: (i) the power to direct the activities of the VIE that most significantly impact the entity’s economic performance; and (ii) the obligation to absorb losses or the right to receive benefits of the VIE that could be significant to the entity. The Company performs this analysis on an ongoing basis.
The Company determines whether an entity is a VIE at the inception of its variable interest in the entity and upon the occurrence of certain reconsideration events.
Management of the Company has determined that Turning Point Brands Canada and ALP Supply Co, LLC (“ALP”) are VIEs for which the Company is required to consolidate and determined that the distribution business acquired by General Wireless Operations, Inc. ("GWO") (refer to Note 7, "Other Assets") is a VIE for which the Company is not required to consolidate. The Company has a
Subsequent to the acquisition of the distribution business by GWO, the Company determined that the GWO equity method investment is a VIE of which we are not the primary beneficiary. We considered the Company’s interest at risk due to a lack of power, through voting rights, to direct the activities that most significantly impact GWO's economic performance. Standard General, L.P’s voting rights are conveyed through an equity interest that is not considered at risk. Based on the foregoing, management believes in its judgement that GWO is a VIE for which the Company is not required to consolidate.
Revenue Recognition
The Company recognizes revenues in accordance with Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers, which includes excise taxes and shipping and handling charges billed to customers, net of cash discounts for prompt payment, sales returns and incentives, upon delivery of goods to the customer – at which time the Company’s performance obligation is satisfied - at an amount that the Company expects to be entitled to in exchange for those goods in accordance with the five-step analysis outlined in ASC 606: (i) identify the contract with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue when (or as) performance obligations are satisfied. The Company includes in its transaction price excise taxes on smokeless tobacco, cigars or other nicotine products billed to customers, and excludes sales taxes and value-added taxes imposed at the time of sale.
The Company records an allowance for sales returns, based principally on historical volume and return rates, which is included in accrued liabilities on the consolidated balance sheets. The Company records sales incentives, which consist of consumer incentives and trade promotion activities, as a reduction in revenues (a portion of which is based on amounts estimated to be due to wholesalers, retailers and consumers at the end of the period) based principally on historical volume and utilization rates. Expected payments for sales incentives are included in accrued liabilities on the consolidated balance sheets.
A further requirement of ASC 606 is for entities to disaggregate revenue recognized from contracts with customers into categories that depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. The Company’s management views business performance through segments that closely resemble the performance of major product lines. Thus, the primary and most useful disaggregation of the Company’s contract revenue for decision making purposes is the disaggregation by segment which can be found in Note 14, “Segment Information”.
Shipping Costs
The Company records shipping costs incurred as a component of selling, general and administrative expenses. Shipping costs incurred were approximately $
Inventories
Inventories are stated at the lower of cost or net realizable value using the first-in, first-out method. Leaf tobacco is presented in current assets in accordance with standard industry practice, notwithstanding the fact that such tobacco is carried longer than one year for the purpose of curing.
Fair Value
U.S. GAAP establishes a framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3).
The three levels of the fair value hierarchy under U.S. GAAP are described below:
| ● | Level 1 – Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets at the measurement date. |
| ● | Level 2 – Inputs to the valuation methodology include quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in inactive markets; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data by correlation or other means. |
| ● | Level 3 – Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. |
Derivative Instruments
From time to time, the Company enters into foreign currency forward contracts to hedge a portion of its exposure to changes in foreign currency exchange rates on inventory purchase commitments. The Company accounts for its forward contracts under the provisions of ASC 815, Derivatives and Hedging. Under the Company’s policy, the Company may hedge up to
Risks and Uncertainties
Manufacturers and sellers of tobacco products are subject to regulation at the federal, state, and local levels. Such regulations include, among others, labeling requirements, limitations on advertising, and prohibition of sales to minors. The tobacco industry is likely to continue to be heavily regulated. There can be no assurance as to the ultimate content, timing, or effect of any regulation of tobacco products by any federal, state, or local legislative or regulatory body, nor can there be any assurance that any such legislation or regulation would not have a material adverse effect on the Company’s financial position, results of operations or cash flows. In a number of states targeted flavor bans have been proposed or enacted legislatively or by the administrative process. Depending on the number and location of such bans, that legislation or regulation could have a material adverse effect on the Company’s financial position, results of operations, or cash flows. The U.S. Food and Drug Administration (“FDA”) continues to consider various restrictive regulations around our products, including targeted flavor bans; however, the details, timing and ultimate implementation of such measures remain unclear.
The tobacco industry has experienced, and is experiencing, significant product liability litigation. Most tobacco liability lawsuits have been brought against manufacturers and sellers of cigarettes for injuries allegedly caused by smoking or exposure to smoke. However, several lawsuits have been brought against manufacturers and sellers of smokeless products for injuries to health allegedly caused by use of smokeless products. Typically, such claims assert that use of smokeless products is addictive and causes oral cancer. There can be no assurance the Company will not sustain losses in connection with such lawsuits and that such losses will not have a material adverse effect on the Company’s financial position, results of operations, or cash flows.
Master Settlement Agreement (MSA)
Pursuant to the Master Settlement Agreement (the “MSA”) entered into in November 1998 by most states (represented by their attorneys general acting through the National Association of Attorneys General) and subsequent states’ statutes, a “cigarette manufacturer” (which is defined to include a manufacturer of make-your-own (“MYO”) cigarette tobacco) has the option of either becoming a signatory to the MSA or opening, funding and maintaining an escrow account to have funds available for certain potential tobacco-related liabilities with sub-accounts on behalf of each settling state. Such companies are entitled to direct the investment of the escrowed funds and withdraw any appreciation but cannot withdraw the principal for years from the year of each annual deposit, except to withdraw funds deposited pursuant to an individual state’s escrow statute to pay a final judgement to that state’s plaintiffs in the event of such a final judgement against the Company. The Company chose to open and fund an escrow account as its method of compliance. It is the Company’s policy to record amounts on deposit in the escrow account for prior years as a non-current asset. The Company has begun to receive deposits back from participating states commencing with the deposits from 1999. At June 30, 2026 and December 31, 2025, the Company had on deposit approximately $
The Company has chosen to invest a portion of the MSA escrow, from time to time, in U.S. Government securities including Treasury inflation-protected securities, Treasury notes and Treasury bonds. These investments are classified as available-for-sale and carried at fair value. Realized losses are prohibited under the MSA; thus, any investment with an unrealized loss position will be held until the value is recovered, or until maturity.
Fair values for the U.S. Governmental agency obligations are Level 2 in the fair value hierarchy. The following tables show cost and estimated fair value of the assets held in the MSA account, respectively, as well as the maturities of the U.S. Governmental agency obligations held in such account for the periods indicated.
| As of June 30, 2026 | As of December 31, 2025 | |||||||||||||||||||||||||||||||
| Gross | Gross | Estimated | Gross | Gross | Estimated | |||||||||||||||||||||||||||
| Unrealized | Unrealized | Fair | Unrealized | Unrealized | Fair | |||||||||||||||||||||||||||
| Cost | Gains | Losses | Value | Cost | Gains | Losses | Value | |||||||||||||||||||||||||
| Cash and cash equivalents | $ | $ | $ | $ | $ | $ | $ | $ | ||||||||||||||||||||||||
| U.S. Governmental agency obligations (unrealized position < 12 months) | ||||||||||||||||||||||||||||||||
| U.S. Governmental agency obligations (unrealized position > 12 months) | ( | ) | ( | ) | ||||||||||||||||||||||||||||
| $ | $ | $ | ( | ) | $ | $ | $ | $ | ( | ) | $ | |||||||||||||||||||||
| As of | ||||
| Maturities: | June 30, 2026 | |||
| Less than one year | $ | |||
| One to five years | ||||
| Five to ten years | ||||
| Greater than ten years | ||||
| Total | $ | |||
The following shows the amount of deposits by sales year for the MSA escrow account:
| Deposits as of | ||||||||
| Sales | June 30, | December 31, | ||||||
| Year | 2026 | 2025 | ||||||
| 1999 | $ | |||||||
| 2000 | ||||||||
| 2001 | ||||||||
| 2002 | ||||||||
| 2003 | ||||||||
| 2004 | ||||||||
| 2005 | ||||||||
| 2006 | ||||||||
| 2007 | ||||||||
| 2008 | ||||||||
| 2009 | ||||||||
| 2010 | ||||||||
| 2011 | ||||||||
| 2012 | ||||||||
| 2013 | ||||||||
| 2014 | ||||||||
| 2015 | ||||||||
| 2016 | ||||||||
| 2017 | ||||||||
| Total | $ | $ | ||||||
Recent Accounting Pronouncements
Issued but not yet adopted
In November 2024, the FASB issued guidance requiring reporting entities to disclose in the notes to the financial statements, specified information about certain categories of expenses including purchases of inventory, employee compensation, depreciation and amortization for each caption on the income statement where such expenses are included. This guidance will be effective for the Company beginning with its fiscal 2027 annual financial statements and interim periods thereafter. Early adoption is permitted, in addition to either prospective or retrospective application. The Company is currently assessing the impact and extent to which this guidance will affect its disclosures.
In December 2025, the FASB issued ASU 2025‑12, which makes targeted technical corrections and clarifications to several topics in the Codification, including diluted EPS, leases, and transfers of receivables. The guidance is effective for annual periods beginning after December 15, 2026, and interim periods within those annual periods. The Company does not expect adoption to have a material impact on its consolidated financial statements.
In September 2025, the FASB issued ASU 2025‑06, which updates the accounting guidance for internal‑use software by eliminating the traditional development stage model and requiring capitalization of costs when funding is authorized and completion is probable, unless significant uncertainties exist. The standard is effective for annual reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of adoption on its consolidated financial statements and disclosures.
Note 3. Fair Value of Financial Instruments
The estimated fair value amounts have been determined by the Company using the methods and assumptions described below. However, considerable judgment is required to interpret market data to develop estimates of fair value. Accordingly, the estimates presented herein are not necessarily indicative of the amounts the Company could realize in a current market exchange. The use of different market assumptions and/or estimation methodologies may have a material effect on the estimated fair value amounts.
Cash and Cash Equivalents
Cash and cash equivalents are, by definition, short-term. Thus, the carrying amount is a reasonable estimate of fair value.
Accounts Receivable
The fair value of accounts receivable approximates their carrying value due to their short-term nature.
Long-Term Debt
The Company's 2032 Notes bear interest at a rate of
See Note 9, “Notes Payable and Long-Term Debt”, for further information regarding the Company’s long-term debt.
Note 4. Inventories
The components of inventories are as follows:
| June 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| Raw materials and work in process | $ | $ | ||||||
| Leaf tobacco | ||||||||
| Finished goods - Zig-Zag products | ||||||||
| Finished goods - Stoker’s products | ||||||||
| Other | ||||||||
| Inventories, net | $ | $ | ||||||
The valuation allowance to write inventory down to its net realizable value at June 30, 2026 and December 31, 2025 was $
In December 2023, a third-party warehouse in Tennessee used by the Company incurred significant tornado damage resulting in damage to the leaf tobacco. The leaf tobacco inventory is covered by the Company’s stock throughput insurance policy and the Company believes the inventory loss is probable of being fully recovered under the policy. As a result, the Company recorded a $
Note 5. Other Current Assets
Other current assets consist of:
| June 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| Inventory deposits | $ | $ | ||||||
| Prepaid taxes | ||||||||
| Insurance recovery receivable | ||||||||
| Other | ||||||||
| Total | $ | $ | ||||||
Note 6. Property, Plant, and Equipment
Property, plant, and equipment consists of:
| June 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| Land | $ | $ | ||||||
| Buildings and improvements | ||||||||
| Leasehold improvements | ||||||||
| Machinery and equipment | ||||||||
| Furniture and fixtures | ||||||||
| Gross property, plant and equipment | ||||||||
| Accumulated depreciation | ( | ) | ( | ) | ||||
| Property, plant and equipment, net | $ | $ | ||||||
Note 7. Other Assets
Other assets consist of:
| June 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| Non-marketable equity investments | $ | $ | ||||||
| Debt security investments | ||||||||
| Capitalized software | ||||||||
| Captive investments - available-for-sale marketable securities | ||||||||
| Option Agreements | ||||||||
| Other | ||||||||
| Total | $ | $ | ||||||
Non-Marketable Equity Investments and Option Agreements
The Company records its non-marketable equity investments without a readily determinable fair value, that are not accounted for under the equity method, at cost, with adjustments for impairment and observable price changes. Should assumptions underlying the determination of the fair values of the Company’s non-marketable equity and debt security investments change, it could result in material future impairment charges.
In December 2018, the Company acquired a minority interest in General Wireless Operations, Inc. (“GWO”) from SG Gaming LLC for $
In August 2025, the Company and Standard General, LP amended the GWO purchase option held by the Company, delaying the Company's ability to exercise the purchase option until August 2027.
Debt Security Investments
In July 2021, the Company invested $
Captive Investments - Available-for-Sale Marketable Securities
In December 2023, the Company formed a captive insurance company, Interchange, IC, incorporated in the District of Columbia, to write a portion of its insurance coverage, including with respect to general product, and officer and director liability coverages under deductible reinsurance policies. Interchange, IC is a fully licensed captive insurance company holding a certificate of authority from the District of Columbia Department of Insurance, Securities and Banking. Interchange, IC is consolidated in the Company’s financial statements. Subsequent to June 30, 2025, Interchange IC received approval from the District of Columbia Department of Insurance, Securities and Banking to operate as a group captive. On July 14, 2025, a third-party investor subscribed for an interest in Interchange IC’s parent company for $
The investments held within the captive are not available for operating activities and are carried at fair value on the consolidated balance sheet. They consist of money market, stocks, corporate bonds, government securities and real estate investment trusts. The Company believes any investments held with gross unrealized losses to be temporary and not the result of credit risk.
The Company’s captive investments are summarized in the following table (excludes money market funds):
| As of June 30, 2026 | As of December 31, 2025 | |||||||||||||||||||||||
| Gross | Estimated | Gross | Estimated | |||||||||||||||||||||
| Amortized | Unrealized | Fair | Amortized | Unrealized | Fair | |||||||||||||||||||
| Cost | Gains (Losses) | Value | Cost | Gains (Losses) | Value | |||||||||||||||||||
| Stocks | $ | $ | $ | $ | $ | $ | ||||||||||||||||||
| Exchange traded funds | ( | ) | ||||||||||||||||||||||
| Corporate bonds | ( | ) | ||||||||||||||||||||||
| Real estate investment trusts | ( | ) | ||||||||||||||||||||||
| Mutual Funds | ( | ) | ||||||||||||||||||||||
| Total | $ | $ | $ | $ | $ | $ | ||||||||||||||||||
The following table summarizes the fair value of the Company’s captive investments by contractual maturity.
| As of | ||||
| June 30, 2026 | ||||
| Due in one to five years | $ | |||
| Stocks, real estate investment trusts, mutual funds, and exchange traded funds | ||||
| Total investments at fair value | $ | |||
Note 8. Accrued Liabilities
Accrued liabilities consists of:
| June 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| Accrued payroll and related items | $ | $ | ||||||
| Customer returns and allowances | ||||||||
| Taxes payable | ||||||||
| Lease liabilities | ||||||||
| Accrued interest | ||||||||
| Option agreement | ||||||||
| Other | ||||||||
| Total | $ | $ | ||||||
Note 9. Notes Payable and Long-Term Debt
Notes payable and long-term debt consists of the following in order of preference:
| June 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| 2032 Notes | $ | $ | ||||||
| Less deferred financing costs | ( | ) | ( | ) | ||||
| Notes payable and long-term debt | $ | $ | ||||||
The components of interest expense, net consists of the following:
| Three Months Ended | Six Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Interest expense | $ | $ | $ | $ | ||||||||||||
| Interest income | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Interest expense, net | $ | $ | $ | $ | ||||||||||||
2032 Notes
On February 19, 2025, the Company entered into an indenture relating to the issuance and sale of $
The 2032 Notes are fully and unconditionally guaranteed on a senior secured basis, jointly and severally, by certain existing and future wholly-owned domestic subsidiaries of the Company (collectively, the “Guarantors” as defined in the indenture governing the 2032 Notes or the “2032 Notes Indenture”). The 2032 Notes and the related guarantees are secured by first-priority liens on substantially all of the existing and future assets of the Company and the Guarantors that do not secure the 2023 ABL Facility (as defined below), subject to certain exceptions. The 2032 Notes Indenture contains covenants that, among other things, restrict the ability of the Company and its restricted subsidiaries to: (i) grant or incur liens; (ii) incur, assume or guarantee additional indebtedness; (iii) sell or otherwise dispose of assets, including capital stock of subsidiaries; (iv) make certain investments; (v) pay dividends, make distributions or redeem or repurchase capital stock; (vi) engage in certain transactions with affiliates; and (vii) consolidate or merge with or into, or sell substantially all of our assets to another entity. These covenants are subject to several limitations and exceptions set forth in the 2032 Notes Indenture. For instance, the Company is generally permitted to make restricted payments, including the payment of dividends to shareholders, provided that, at the time of payment, or as a result of payment, the Company is not in default on its covenants; however, there are earnings and market capitalization requirements that if not met could limit the aggregate amount of quarterly dividends payable during a fiscal year. The 2032 Notes Indenture provides for customary events of default. The Company was in compliance with all covenants under the 2032 Notes as of June 30, 2026.
The Company incurred debt issuance costs attributable to the 2032 Notes of $
2023 ABL Facility
On November 7, 2023, TPB Specialty Finance, LLC, a wholly-owned subsidiary of the Company (the “ABL Borrower”), entered into a new $
The 2023 ABL Facility contains customary borrowing conditions including a borrowing base equal to the sum of (a) the lesser of (1)
Amounts borrowed under the 2023 ABL Facility are subject to an interest rate margin per annum equal to (a) from and after the closing date until the last day of the first full fiscal quarter ended after the closing date, (i)
| Applicable Margin | Applicable Margin | ||||||
| Level | Historical Excess Availability | for SOFR Loans | for Base Rate Loans | ||||
| I | Greater than or equal to 66.66% | ||||||
| II | Less than 66.66%, but greater than or equal to 33.33% | ||||||
| III | Less than 33.33% |
The 2023 ABL Facility also requires the Company and its restricted subsidiaries to maintain a fixed charge coverage ratio of at least
The 2023 ABL Facility matures on the earlier of (x) November 7, 2027 and (y) the date that is
The Company has drawn any borrowings under the 2023 ABL Facility but has letters of credit of approximately $
The Company incurred debt issuance costs attributable to the 2023 ABL Facility of $
Note 10. Income Taxes
The Company’s effective income tax rate for the three and six months ended June 30, 2026 was
During the first quarter of 2026, the Company concluded that it was more‑likely‑than‑not that TPBI’s separate company state net operating losses and other deferred tax assets, excluding the State §163(j) interest limitation carryforward, would be realizable. As a result, the Company released $
Note 11. Share Incentive Plans
On March 22, 2021, the Company’s Board of Directors adopted the Turning Point Brands, Inc. 2021 Equity Incentive Plan (the “2021 Plan”), pursuant to which awards may be granted to employees, non-employee directors, and consultants. In addition, the 2021 Plan provides for the granting of nonqualified stock options to employees of the Company or any subsidiary of the Company. Pursuant to the 2021 Plan,
On April 28, 2016, the Board of Directors of the Company adopted the 2015 Plan, pursuant to which awards could have been granted to employees, non-employee directors, and consultants. In addition, the 2015 Plan provided for the granting of nonqualified stock options to employees of the Company or any subsidiary of the Company. Upon adoption of the 2021 Plan, the 2015 Plan was terminated, and the Company determined no additional grants would be made under the 2015 Plan. However, all awards issued under the 2015 Plan that have not been previously terminated or forfeited remain outstanding and continue unaffected. There are
Stock option activity for the 2015 and 2021 Plans is summarized below:
| Weighted | Weighted | |||||||||||
| Stock | Average | Average | ||||||||||
| Option | Exercise | Grant Date | ||||||||||
| Shares | Price | Fair Value | ||||||||||
| Outstanding, December 31, 2024 | $ | $ | ||||||||||
| Exercised | ( | ) | ||||||||||
| Forfeited | ( | ) | ||||||||||
| Outstanding, December 31, 2025 | $ | $ | ||||||||||
| Exercised | ( | ) | ||||||||||
| Outstanding, June 30, 2026 | $ | $ | ||||||||||
Under the 2015 and 2021 Plans, the total intrinsic value of options exercised during the six months ended June 30, 2026 and 2025, was $
At June 30, 2026, under the 2015 and 2021 Plans, the risk-free interest rate is based on the U.S. Treasury rate for the expected life at the time of grant. The expected volatility is based on the average long-term historical volatilities of peer companies. We intend to continue to consistently use the same group of publicly traded peer companies to determine expected volatility until sufficient information regarding volatility of our share price becomes available or until the selected companies are no longer suitable for this purpose. Due to our limited trading history, we are using the simplified method presented by SEC Staff Accounting Bulletin No. 107 to calculate expected holding periods, which represent the periods of time for which options granted are expected to be outstanding. We will continue to use this method until we have sufficient historical exercise experience to give us confidence in the reliability of our calculations. The fair values of these options were determined using the Black-Scholes option pricing model.
The following table outlines the assumptions based on the number of options granted under the 2015 Plan.
| May 17, | March 7, | March 20, | March 18, | February 18, | ||||||||||||||||
| 2017 | 2018 | 2019 | 2020 | 2021 | ||||||||||||||||
| Number of options granted | ||||||||||||||||||||
| Options outstanding at June 30, 2026 | ||||||||||||||||||||
| Number exercisable at June 30, 2026 | ||||||||||||||||||||
| Exercise price | $ | $ | $ | $ | $ | |||||||||||||||
| Remaining lives | ||||||||||||||||||||
| Risk free interest rate | % | % | % | % | % | |||||||||||||||
| Expected volatility | % | % | % | % | % | |||||||||||||||
| Expected life | ||||||||||||||||||||
| Dividend yield | % | % | % | % | ||||||||||||||||
| Fair value at grant date | $ | $ | $ | $ | $ | |||||||||||||||
The following table outlines the assumptions based on the number of options granted under the 2021 Plan.
| March 14, | April 29, | May 12, | March 11, | |||||||||||||
| 2022 | 2022 | 2023 | 2024 | |||||||||||||
| Number of options granted | ||||||||||||||||
| Options outstanding at June 30, 2026 | ||||||||||||||||
| Number exercisable at June 30, 2026 | ||||||||||||||||
| Exercise price | $ | $ | $ | $ | ||||||||||||
| Remaining lives | ||||||||||||||||
| Risk free interest rate | % | % | % | % | ||||||||||||
| Expected volatility | % | % | % | % | ||||||||||||
| Expected life | ||||||||||||||||
| Dividend yield | % | % | % | % | ||||||||||||
| Fair value at grant date | $ | $ | $ | $ | ||||||||||||
The Company records compensation expense related to the options based on the provisions of ASC 718 under which the fixed portion of such expense is determined as the fair value of the options on the date of grant and amortized over the vesting period. In 2026 and 2025, the Company has recorded
PRSUs are restricted stock units subject to both performance-based and service-based vesting conditions. The number of shares of TPB Common Stock a recipient will receive upon vesting of a PRSU will be calculated by reference to certain performance metrics related to the Company’s performance over a -year period. PRSUs will vest on the measurement date, which is no more than
| March 14, | March 1, | April 1, | March 3, | March 3, | ||||||||||||||||
| 2022 | 2024 | 2024 | 2025 | 2026 | ||||||||||||||||
| Number of PRSUs granted | ||||||||||||||||||||
| PRSUs outstanding at June 30, 2026 | ||||||||||||||||||||
| Fair value as of grant date | $ | $ | $ | $ | $ | |||||||||||||||
| Remaining lives | ||||||||||||||||||||
The Company records compensation expense related to the PRSUs based on the probability of achieving the performance condition. The Company recorded compensation expense related to the PRSUs of approximately $
The Company has granted
| March 14, | April 29, | March 1, | April 1, | March 3, | July 14, | March 3, | May 11, | |||||||||||||||||||||||||
| 2022 | 2022 | 2024 | 2024 | 2025 | 2025 | 2026 | 2026 | |||||||||||||||||||||||||
| Number of RSUs granted | ||||||||||||||||||||||||||||||||
| RSUs outstanding at June 30, 2026 | ||||||||||||||||||||||||||||||||
| Fair value as of grant date | $ | $ | $ | $ | $ | $ | $ | $ | ||||||||||||||||||||||||
| Remaining lives | ||||||||||||||||||||||||||||||||
The Company records compensation expense related to the RSUs based on the provisions of ASC 718 under which the fixed portion of such expense is determined as the fair value of the RSUs on the date of grant and amortized over the vesting period. The Company recorded compensation expense related to the RSUs of million and $
Note 12. Contingencies
Other major tobacco companies are defendants in product liability claims. In a number of these cases, the amounts of punitive and compensatory damages sought are significant and, if such a claim were brought against the Company, could have a material adverse effect on our business and results of operations. The potential losses associated with any such lawsuits are not currently reasonably estimable and therefore are not accrued.
Note 13. Income Per Share
The Company calculates earnings per share using the treasury stock method for its options and non-vested restricted stock units.
The following is a reconciliation of the numerators and denominators of the basic and diluted EPS computations of net income:
| Three Months Ended June 30, | ||||||||||||||||||||||||
| 2026 | 2025 | |||||||||||||||||||||||
| Per | Per | |||||||||||||||||||||||
| Income | Shares | Share | Income | Shares | Share | |||||||||||||||||||
| Basic EPS: | ||||||||||||||||||||||||
| Numerator | ||||||||||||||||||||||||
| Net income attributable to Turning Point Brands, Inc. | $ | $ | $ | $ | ||||||||||||||||||||
| Denominator | ||||||||||||||||||||||||
| Weighted average | ||||||||||||||||||||||||
| Diluted EPS: | ||||||||||||||||||||||||
| Numerator | ||||||||||||||||||||||||
| Diluted net income attributable to Turning Point Brands, Inc. | $ | $ | 0.18 | $ | $ | 0.79 | ||||||||||||||||||
| Denominator | ||||||||||||||||||||||||
| Basic weighted average | ||||||||||||||||||||||||
| Stock options and restricted stock units | ||||||||||||||||||||||||
| Six Months Ended June 30, | ||||||||||||||||||||||||
| 2026 | 2025 | |||||||||||||||||||||||
| Per | Per | |||||||||||||||||||||||
| Income | Shares | Share | Income | Shares | Share | |||||||||||||||||||
| Basic EPS: | ||||||||||||||||||||||||
| Numerator | ||||||||||||||||||||||||
| Net income attributable to Turning Point Brands, Inc. | $ | $ | $ | $ | ||||||||||||||||||||
| Denominator | ||||||||||||||||||||||||
| Weighted average | ||||||||||||||||||||||||
| Diluted EPS: | ||||||||||||||||||||||||
| Numerator | ||||||||||||||||||||||||
| Diluted net income attributable to Turning Point Brands, Inc. | $ | $ | 0.77 | $ | $ | 1.58 | ||||||||||||||||||
| Denominator | ||||||||||||||||||||||||
| Basic weighted average | ||||||||||||||||||||||||
| Stock options and restricted stock units | ||||||||||||||||||||||||
Note 14. Segment Information
In accordance with ASC 280, Segment Reporting, the Company has reportable segments, Zig-Zag products and Stoker’s products. The Zig-Zag products segment markets and distributes (i) rolling papers, tubes, and related products; (ii) finished cigars and MYO cigar wraps; and (iii) lighters and other accessories. The Stoker’s products segment (i) manufactures and markets moist snuff, (ii) contracts for and markets loose-leaf chewing tobacco products, and (iii) contracts for and markets its modern oral product. The Company's products are distributed primarily through wholesale distributors in the U.S. and Canada. Corporate unallocated includes the costs and assets of the Company not assigned to one of the reportable segments and includes corporate overhead expense, including executive management, finance, legal and information technology salaries, and professional services such as audit, external legal costs and information technology services, as well as costs related to the FDA premarket tobacco product application.
The Company’s CODM is its President and Chief Executive Officer who uses segment operating income as the measure of earnings to evaluate the performance of each segment and to make decisions about allocating resources, including employees, property, plant and equipment, as well as financial and capital resources. On a quarterly basis, the CODM reviews segment operating income budget-to-actual variances to assess segment performance and make resource allocation decisions. For both reportable segments, cost of sales is the significant segment expense that is regularly provided to the CODM.
The accounting policies of these segments are the same as those of the Company. Corporate costs are directly charged to the reportable segments in the ordinary course of operations.
The tables below present financial information about reportable segments:
| Three Months Ended | Six Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Net sales | ||||||||||||||||
| Zig-Zag products | $ | $ | $ | $ | ||||||||||||
| Stoker’s products | ||||||||||||||||
| Total | $ | $ | $ | $ | ||||||||||||
| Cost of Sales | ||||||||||||||||
| Zig-Zag products (1) | $ | $ | $ | $ | ||||||||||||
| Stoker’s products (2) | ||||||||||||||||
| Total | $ | $ | $ | $ | ||||||||||||
| Gross profit | ||||||||||||||||
| Zig-Zag products | $ | $ | $ | $ | ||||||||||||
| Stoker’s products | ||||||||||||||||
| Total | $ | $ | $ | $ | ||||||||||||
| Other segment items (3) | ||||||||||||||||
| Zig-Zag products | $ | $ | $ | $ | ||||||||||||
| Stoker’s products | ||||||||||||||||
| Total | $ | $ | $ | $ | ||||||||||||
| Operating income (loss) | ||||||||||||||||
| Zig-Zag products | $ | $ | $ | $ | ||||||||||||
| Stoker’s products | ||||||||||||||||
| Total segment operating income | $ | $ | $ | $ | ||||||||||||
| Corporate unallocated (4)(5) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Total | $ | $ | $ | $ | ||||||||||||
| Other expense, net | ||||||||||||||||
| Interest expense, net | ||||||||||||||||
| Investment loss (gain) | ( | ) | ( | ) | ||||||||||||
| (Income) loss from equity method investment | ( | ) | ( | ) | ||||||||||||
| Loss on extinguishment of debt | ||||||||||||||||
| Income from continuing operations before income taxes | $ | $ | $ | $ | ||||||||||||
| Capital expenditures | ||||||||||||||||
| Zig-Zag products | $ | $ | $ | $ | ||||||||||||
| Stoker’s products | ||||||||||||||||
| Total | $ | $ | $ | $ | ||||||||||||
| Depreciation and amortization | ||||||||||||||||
| Zig-Zag products | $ | $ | $ | $ | ||||||||||||
| Stoker’s products | ||||||||||||||||
| Total | $ | $ | $ | $ | ||||||||||||
| (1) | Cost of sales reduced by tariff refund of $ |
| (2) | Cost of sales reduced by tariff refund of $ |
| (3) | Includes primarily selling and marketing costs. |
| (4) | Includes corporate costs that are not allocated to any of the two reportable segments. |
| (5) | Includes costs related to FDA premarket tobacco product application (“PMTA”) of $ |
| June 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| Assets | ||||||||
| Zig-Zag products | $ | $ | ||||||
| Stoker’s products | ||||||||
| Corporate unallocated (1) | ||||||||
| Total | $ | $ | ||||||
| (1) | Includes assets not assigned to the reportable segments. All goodwill has been allocated to the reportable segments. |
Net Sales: Domestic and Foreign
The following table shows a breakdown of consolidated net sales between domestic and foreign customers:
| Three Months Ended | Six Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Domestic | $ | $ | $ | $ | ||||||||||||
| Foreign | ||||||||||||||||
| Total | $ | $ | $ | $ | ||||||||||||
Note 15. Dividends and Shares Repurchases
A dividend of $
The Company currently pays a quarterly cash dividend. Dividends are considered restricted payments under the 2032 Notes Indenture. The Company is generally permitted to make restricted payments provided that, at the time of payment, or as a result of payment, the Company is not in default on its debt covenants; however, there are earnings and market capitalization requirements that if not met could limit the aggregate amount of restricted, quarterly dividends during a fiscal year.
On February 25, 2020, the Company’s Board of Directors approved a $
The Company entered into an at-the-market offering program (the "ATM Program") on December 13, 2024, with B. Riley Securities Inc. and Barclays Capital Inc. The Company filed an amendment to the prospectus supplement on November 2, 2025 to increase the aggregate dollar amount of shares of common stock that it may sell under the ATM Program by an additional $
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
You should read the following discussion of the historical financial conditions and results of operations in conjunction with our consolidated financial statements and accompanying notes, which are included elsewhere in this Quarterly Report on Form 10-Q. In addition, this discussion includes forward-looking statements which are subject to risks and uncertainties that may result in actual results differing from statements we make. See “Cautionary Note Regarding Forward-Looking Statements.” Factors that could cause actual results to differ include those risks and uncertainties discussed in “Risk Factors” contained in the Annual Report on Form 10-K for the fiscal year ended December 31, 2025.
The following Management’s Discussion and Analysis (“MD&A”) relates to the unaudited financial statements of Turning Point Brands, Inc., included elsewhere in this Quarterly Report on Form 10-Q. The MD&A is intended to enable the reader to understand the Company’s financial condition and results of operations, including any material changes in the Company’s financial condition and results of operations since December 31, 2025, and as compared with the three and six months ended June 30, 2025. The MD&A is provided as a supplement to and should be read in conjunction with the unaudited consolidated financial statements and notes thereto included in this Quarterly report on Form 10-Q, as well as “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contained in the Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the “2025 Annual Report”).
In this MD&A, unless the context requires otherwise, references to “our Company” “we,” “our,” or “us” refer to Turning Point Brands, Inc., and its consolidated subsidiaries. References to “TPB” refer to Turning Point Brands, Inc., without any of its subsidiaries. Many of the amounts and percentages in this discussion have been rounded for convenience of presentation.
Overview
Turning Point Brands, Inc. is a leading manufacturer, marketer and distributor of branded consumer products. We sell a wide range of products to adult consumers consisting of staple products with our iconic brands Zig-Zag® and Stoker’s® and our next-generation products to fulfill evolving consumer preferences. Among other markets, we compete in the alternative smoking accessories and Other Tobacco Products (“OTP”) industries. The alternative smoking accessories market is a dynamic market experiencing robust secular growth driven by cannabinoid legalization in the U.S. and Canada and positively evolving consumer perception and acceptance in North America. The OTP industry, which consists of non-cigarette tobacco products, exhibited flat consumer unit annualized growth during the full year period ended 2025 as reported by MSAi a third-party analytics and information company. Our segments are led by our core proprietary and iconic brands: Zig-Zag® in the Zig-Zag products segment and Stoker’s® along with FRE®, Beech-Nut® and Trophy® in the Stoker’s products segment. Our businesses generate solid cash flow which we use to invest in our business, finance acquisitions, increase brand support, expand our distribution infrastructure, and strengthen our capital position. We currently ship to approximately 900 distributors with an additional approximately 600 secondary, indirect wholesalers in the U.S. that carry and sell our products. Under the leadership of a senior management team with extensive experience in the consumer products, alternative smoking accessories and tobacco industries, we have grown and diversified our business through new product launches, category expansions and acquisitions while concurrently improving operational efficiency.
We believe there are meaningful opportunities to expand through investing in organic growth via acquisitions and joint ventures across all product categories. Our products are currently available in approximately 220,000 retail locations in North America. Our sales team targets widespread distribution to all traditional retail channels, including convenience stores, and we have a growing e-commerce business.
Recent Developments
On February 20, 2026, the U.S. Supreme Court issued a ruling regarding tariffs imposed under the International Emergency Economic Powers Act ("IEEPA") on goods imported into the United States, concluding that such tariffs were unauthorized. The Company paid approximately $17.9 million in IEEPA tariffs.
The ruling did not address the availability, timing, or amount of any potential refunds. Subsequently, the U.S. Court of International Trade ("CIT") ordered U.S. Customs and Border Protection ("CBP") to refund the collected IEEPA tariffs. On April 20, 2026, CBP launched the Consolidated Administration and Processing of Entries ("CAPE") system to facilitate IEEPA tariff refunds. In June 2026, the Company received approximately $17.8 million of tariff refunds from CBP related to previously paid IEEPA tariffs. The refund consisted of $5.5 million in costs that were capitalized and on the balance sheet with the remaining $12.3 million recognized as a reduction of cost of goods sold.
The Company continues to monitor developments related to the ruling, including any ongoing legal, regulatory, or administrative actions. In addition, following the U.S. Supreme Court's decision, the U.S. administration announced additional tariffs under Section 122 of the Trade Act of 1974 and could implement additional tariffs in the future. Changes in U.S. and foreign trade, import, and export policies could have a material impact on the Company's financial position, results of operations, and cash flows.
Products
We operate in two segments: Zig-Zag products and Stoker’s products segments. In our Zig-Zag products segment, we principally market and distribute (i) rolling papers, tubes and related products; (ii) finished cigars and make-your-own (“MYO”) cigar wraps; and (iii) lighters and other accessories. In addition, we have a majority stake in Turning Point Brands Canada which is a specialty marketing and distribution firm focused on building brands in the Canadian cannabis accessories, tobacco and alternative products categories. In our Stoker’s products segment, we (i) manufacture and market moist snuff tobacco (“MST”); (ii) contract for and market modern oral products; and (iii) contract for and market loose-leaf chewing tobacco products.
Operations
Our Zig-Zag products and Stoker’s products segments primarily generate revenues from the sale of our products to wholesale distributors who, in turn, resell the products to retail operations. Our net sales, which include federal excise taxes, consist of gross sales net of cash discounts, returns, and selling and marketing allowances.
We rely on long-standing relationships with high-quality, established manufacturers to provide the majority of our produced products. Approximately 75% of our production, as measured by net sales, is outsourced to suppliers. The remaining production consists primarily of our moist snuff tobacco operations located in Dresden, Tennessee and Louisville, Kentucky. Our principal operating expenses include the cost of raw materials used to manufacture the limited number of our products which we produce in-house; the cost of finished products, which are generally purchased goods; federal excise taxes; legal expenses; and compensation expenses, including benefits and costs of salaried personnel.
Key Factors Affecting Our Results of Operations
We consider the following to be the key factors affecting our results of operations:
| ● |
Our ability to further penetrate markets with our existing products; |
| ● |
Our ability to introduce new products and product lines that complement our core business; |
| ● |
Decreasing interest in some tobacco products among consumers; |
|
| ● | Competition; |
| ● |
Price sensitivity in our end-markets; |
| ● |
Marketing and promotional initiatives, which cause variability in our results; |
| ● |
Cost related to increasing regulation of promotional and advertising activities; |
| ● |
General economic conditions, including consumer access to disposable income and other conditions affecting purchasing power such as inflation and the interest rate environment; |
| ● |
Labor and production costs; |
| ● |
Cost of complying with regulation, including the “deeming regulation”, as well as the unpredictable nature of the regulatory regimes; |
| ● |
Changes to U.S. trade policies, including tariff policies, as well as the unpredictable nature and legality of tariff schemes; |
| ● |
Counterfeit and other illegal products in our end-markets; |
| ● |
Currency fluctuations; |
| ● |
Our ability to identify attractive acquisition opportunities; and |
| ● |
Our ability to successfully integrate acquisitions. |
Critical Accounting Policies and Uses of Estimates
There have been no material changes to our critical accounting policies and estimates from the information provided in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our 2025 Annual Report on Form 10-K.
Recent Accounting Pronouncements
See Item 1 of Part I, “Notes to Consolidated Financial Statements - Note 2 - Summary of Significant Accounting Policies - Recent Accounting Pronouncements.”
Results of Operations
Summary
The table and discussion set forth below relates to our consolidated results of continuing operations:
| (in thousands) |
Three Months Ended June 30, | |||||||||||
| 2026 |
2025 |
% Change |
||||||||||
| Consolidated Results of Operations Data: |
||||||||||||
| Net sales |
||||||||||||
| Zig-Zag products |
$ | 35,381 | $ | 47,018 | -24.8 | % | ||||||
| Stoker’s products |
107,579 | 69,616 | 54.5 | % | ||||||||
| Total net sales |
142,960 | 116,634 | 22.6 | % | ||||||||
| Cost of sales |
49,256 | 50,011 | -1.5 | % | ||||||||
| Gross profit |
||||||||||||
| Zig-Zag products |
22,623 | 23,099 | -2.1 | % | ||||||||
| Stoker’s products |
71,081 | 43,524 | 63.3 | % | ||||||||
| Total gross profit |
93,704 | 66,623 | 40.6 | % | ||||||||
| Selling, general, and administrative expenses |
76,991 | 40,296 | 91.1 | % | ||||||||
| Operating income |
||||||||||||
| Zig-Zag products |
8,751 | 14,741 | -40.6 | % | ||||||||
| Stoker’s products |
29,929 | 30,079 | -0.5 | % | ||||||||
| Total segment operating income |
38,680 | 44,820 | -13.7 | % | ||||||||
| Corporate unallocated |
(21,967 | ) | (18,493 | ) | 18.8 | % | ||||||
| Total operating income |
16,713 | 26,327 | -36.5 | % | ||||||||
| Other expense, net |
63 | - | NM | |||||||||
| Interest expense, net |
4,251 | 5,140 | -17.3 | % | ||||||||
| Investment loss (gain) |
1,089 | (78 | ) | -1496.2 | % | |||||||
| (Income) loss from equity method investment |
(2,674 | ) | 61 | NM | ||||||||
| Income from continuing operations before income taxes |
13,984 | 21,204 | -34.1 | % | ||||||||
| Income tax (benefit) expense |
3,683 | 4,244 | -13.2 | % | ||||||||
| Consolidated net income from continuing operations |
10,301 | 16,960 | -39.3 | % | ||||||||
| Net income attributable to non-controlling interest |
6,703 | 2,480 | 170.3 | % | ||||||||
| Net income from continuing operations attributable to Turning Point Brands, Inc. |
$ | 3,598 | $ | 14,480 | -75.2 | % | ||||||
Comparison of the Three Months Ended June 30, 2026, to the Three Months Ended June 30, 2025
Net Sales: For the three months ended June 30, 2026, consolidated net sales increased $26.3 million, or 22.6% compared to the prior year period, driven primarily by an increase in the Stoker’s products segment.
For the three months ended June 30, 2026, net sales in the Zig-Zag products segment decreased $11.6 million, or 24.8% compared to the prior year period. The decrease in net sales was driven primarily by declines of $4.7 million in U.S. papers and wraps, $6.2 million in the Clipper lighter business, and $1.0 million in our Canadian products. We were able to sell the majority of the Clipper inventory in the prior year and do not expect meaningful additional revenue from Clipper in future periods.
For the three months ended June 30, 2026, net sales in the Stoker’s products segment increased $38.0 million, or 54.5% compared to the prior year period. The increase in net sales was primarily driven by $38.4 million of growth in modern oral products.
Gross Profit: For the three months ended June 30, 2026, consolidated gross profit increased $27.1 million, or 40.6% compared to the prior year period. Gross profit as a percentage of net sales increased to 65.5% for the three months ended June 30, 2026, compared to 57.1% for the three months ended June 30, 2025. The overall increase in gross profit was driven by increases in net sales in the Stoker's products segment, margin contribution from modern oral products, and $12.3 million reduction in cost of sales as a result of tariff refunds.
For the three months ended June 30, 2026, gross profit in the Zig-Zag products segment decreased $0.5 million, or 2.1% compared to the prior year period. Gross profit as a percentage of net sales increased to 63.9% of net sales for the three months ended June 30, 2026, from 49.1% of net sales for the three months ended June 30, 2025, driven primarily by product mix and by $2.4 million reduction in cost of sales as a result of tariff refunds.
For the three months ended June 30, 2026, gross profit in the Stoker’s products segment increased $27.6 million, or 63.3% compared to the prior year period. Gross profit as a percentage of net sales increased to 66.1% of net sales for the three months ended June 30, 2026, from 62.5% of net sales for the three months ended June 30, 2025, primarily driven by margin contribution from modern oral products and $9.9 million reduction in cost of sales as a result of tariff refunds.
Selling, General, and Administrative Expenses: For the three months ended June 30, 2026, selling, general, and administrative expenses increased $36.7 million, or 91.1% compared to the prior year period, primarily due to increased shipping and selling costs related to the increase in modern oral sales, increased salaries and benefits resulting from additional sales headcount, and higher sales and advertising expenses to support the modern oral growth in the quarter compared to the prior year period. Selling, general and administrative expenses in the three months ended June 30, 2026, included $3.2 million of expense related to PMTA, $2.7 million of stock options, restricted stock and incentives expense, $0.7 million of legal expenses incurred in connection with litigation related to an insurance claim, and $0.1 million of expense related to corporate restructuring. Selling, general and administrative expenses in the three months ended June 30, 2025, included $1.6 million of stock options, restricted stock and incentives expense, $1.7 million of expense related to PMTA, $0.8 million of elevated non-recurring outbound freight costs due to ERP transition, $0.5 million of legal expenses incurred in connection with litigation related to an insurance claim, and $0.6 million of transaction costs.
Operating Income: For the three months ended June 30, 2026, consolidated operating income decreased $9.6 million, or 36.5% compared to the prior year period. Operating income as a percentage of net sales decreased to 11.7% of net sales for the three months ended June 30, 2026 from 22.6% of net sales for the three months ended June 30, 2025, primarily driven by increased selling, general and administrative costs, partially offset by $12.3 million reduction in cost of sales as a result of tariff refunds.
For the three months ended June 30, 2026, operating income in the Zig-Zag products segment decreased $6.0 million, or 40.6% compared to the prior year period. Operating income as a percentage of net sales decreased to 24.7% of net sales for the three months ended June 30, 2026 from 31.4% of net sales for the three months ended June 30, 2025, primarily driven by an increase in sales and marketing costs, partially offset by $2.4 million reduction in cost of sales as a result of tariff refunds.
For the three months ended June 30, 2026, operating income in the Stoker’s products segment decreased $0.2 million, or 0.5% compared to the prior year period. Operating income as a percentage of net sales decreased to 27.8% of net sales for the three months ended June 30, 2026 from 43.2% of net sales for the three months ended June 30, 2025, primarily driven by higher sales and marketing costs offset by margin contribution of modern oral products and $9.9 million reduction in cost of sales as a result of tariff refunds.
Included in consolidated operating income are costs of the Company which are not assigned to one of the two reportable segments and include: (i) corporate overhead expense, including executive management, finance, legal and information technology salaries, and professional services, such as audit, external legal costs and information technology services, as well as (ii) costs related to the FDA premarket tobacco product application. For the three months ended June 30, 2026, unallocated costs were $22.0 million compared to $18.5 million in the prior year period, an increase of $3.5 million or 18.8%, primarily driven by joint venture related corporate expenses.
Other Expense, net: For the three months ended June 30, 2026, other expense increased $0.1 million compared to the prior year period due to an honorarium gift in the current year period that was not made in the prior year period.
Interest Expense, net: For the three months ended June 30, 2026, interest expense, net decreased $0.9 million or 17.3% due to an increase in interest income as a result of interest of $0.6 million received on the tariff refund.
Investment Loss (Gain): For the three months ended June 30, 2026, investment loss was $1.1 million, compared to $0.1 million investment gain in the prior-year period, primarily driven by higher realized loss from a non-cash valuation adjustment during the period.
Income From Equity Method Investments: For the three months ended June 30, 2026, income from investments in equity securities increased $2.7 million compared to the prior year period as a result of GWO.
Income Tax Expense: Our income tax expense of $3.7 million was 26.3% of income before income taxes for the three months ended June 30, 2026. Our effective income tax rate was 20.0% for the three months ended June 30, 2025. The change in tax rate is primarily attributable to the release of a valuation allowance on deferred tax assets in the current year period.
Net Income Attributable to Non-Controlling Interest: Net income attributable to non-controlling interest was $6.7 million and $2.5 million, respectively, for the three months ended June 30, 2026 and 2025. The increase in non-controlling interest compared to the prior year period is primarily due to higher sales volumes and improved net income of our joint venture.
Net Income Attributable to Turning Point Brands, Inc.: Due to the factors described above, net income attributable to Turning Point Brands, Inc. for the three months ended June 30, 2026 and 2025, was $3.6 million and $14.5 million, respectively.
Summary
The table and discussion set forth below relates to our consolidated results of continuing operations:
| Six Months Ended June 30, |
||||||||||||
| 2026 |
2025 |
% Change |
||||||||||
| Consolidated Results of Operations Data: |
||||||||||||
| Net sales |
||||||||||||
| Zig-Zag products |
$ | 72,050 | $ | 94,283 | -23.6 | % | ||||||
| Stoker’s products |
195,188 | 128,787 | 51.6 | % | ||||||||
| Total net sales |
267,238 | 223,070 | 19.8 | % | ||||||||
| Cost of sales |
105,239 | 96,837 | 8.7 | % | ||||||||
| Gross profit |
||||||||||||
| Zig-Zag products |
43,568 | 48,665 | -10.5 | % | ||||||||
| Stoker’s products |
118,431 | 77,568 | 52.7 | % | ||||||||
| Total gross profit |
161,999 | 126,233 | 28.3 | % | ||||||||
| Selling, general, and administrative expenses |
132,802 | 76,717 | 73.1 | % | ||||||||
| Operating income |
||||||||||||
| Zig-Zag products |
19,982 | 31,672 | -36.9 | % | ||||||||
| Stoker’s products |
49,700 | 54,212 | -8.3 | % | ||||||||
| Total segment operating income |
69,682 | 85,884 | -18.9 | % | ||||||||
| Corporate unallocated |
(40,485 | ) | (36,368 | ) | 11.3 | % | ||||||
| Total operating income |
29,197 | 49,516 | -41.0 | % | ||||||||
| Other (income) expense, net |
126 | - | NM | |||||||||
| Interest expense, net |
8,674 | 9,554 | -9.2 | % | ||||||||
| Investment loss (gain) |
938 | (519 | ) | -280.7 | % | |||||||
| (Income) loss from equity method investment |
(5,657 | ) | 211 | NM | ||||||||
| Loss on extinguishment of debt |
- | 1,235 | NM | |||||||||
| Income from continuing operations before income taxes |
25,116 | 39,035 | -35.7 | % | ||||||||
| Income tax expense |
873 | 6,284 | -86.1 | % | ||||||||
| Consolidated net income from continuing operations |
24,243 | 32,751 | -26.0 | % | ||||||||
| Net income attributable to non-controlling interest |
8,978 | 3,876 | 131.6 | % | ||||||||
| Net income from continuing operations attributable to Turning Point Brands, Inc. |
$ | 15,265 | $ | 28,875 | -47.1 | % | ||||||
Comparison of the Six Months Ended June 30, 2026, to the Six Months Ended June 30, 2025
Net Sales: For the six months ended June 30, 2026, consolidated net sales increased $44.2 million, or 19.8% compared to the prior year period, driven primarily by an increase in the Stoker’s products segment.
For the six months ended June 30, 2026, net sales in the Zig-Zag products segment decreased $22.2 million, or 23.6% compared to the prior year period. The decrease in net sales was driven primarily by declines of $12.0 million in U.S. papers and wraps, $8.0 million in the Clipper lighter business, and $2.0 million in our Canadian products. We were able to sell the majority of the Clipper inventory in the prior year and do not expect meaningful additional revenue from Clipper in future periods.
For the six months ended June 30, 2026, net sales in the Stoker’s products segment increased $66.4million, or 51.6% compared to the prior year period. The increase in net sales was primarily driven by growth in modern oral products.
Gross Profit: For the six months ended June 30, 2026, consolidated gross profit increased $35.8 million, or 28.3% compared to the prior year period. Gross profit as a percentage of net sales increased to 60.6% for the six months ended June 30, 2026, compared to 56.6% for the six months ended June 30, 2025. The overall increase in gross profit was driven by increases in net sales in the Stoker's products segment, margin contribution from modern oral products and $12.3 million reduction in cost of sales as a result of tariff refunds.
For the six months ended June 30, 2026, gross profit in the Zig-Zag products segment decreased $5.1 million, or 10.5% compared to the prior year period. Gross profit as a percentage of net sales increased to 60.5% of net sales for the six months ended June 30, 2026, from 51.6%of net sales for the six months ended June 30, 2025, driven primarily by product mix, and $2.4 million reduction in cost of sales as a result of tariff refunds.
For the six months ended June 30, 2026, gross profit in the Stoker’s products segment increased $40.9 million, or 52.7% compared to the prior year period. Gross profit as a percentage of net sales increased to 60.7% of net sales for the six months ended June 30, 2026, from 60.2% of net sales for the six months ended June 30, 2025, primarily driven by net sales growth, margin contribution from modern oral products and $9.9 million reduction in cost of sales as a result of tariff refunds.
Selling, General, and Administrative Expenses: For the six months ended June 30, 2026, selling, general, and administrative expenses increased $56.1 million, or 73.1% compared to the prior year period primarily due to increased shipping and selling costs related to the increase in modern oral sales, increased salaries and benefits resulting from additional sales headcount, and higher sales and advertising expenses in the current year period compared to the prior year period. Selling, general and administrative expenses in the six months ended June 30, 2026, included $3.5 million of expense related to PMTA, $5.6 million of stock options, restricted stock and incentives expense, $0.8 million of legal expenses incurred in connection with litigation related to an insurance claim, and $0.2 million of expense related to corporate restructuring. Selling, general and administrative expenses in the six months ended June 30, 2025, included $3.2 million of expense related to PMTA, $3.3 million of stock options, restricted stock and incentives expense, $0.7 million of transaction costs, and $0.2 million of expense related to the implementation of the new ERP and CRM systems.
Operating Income: For the six months ended June 30, 2026, consolidated operating income decreased $20.3 million, or 41.0% compared to the prior year period. Operating income as a percentage of net sales decreased to 10.9% of net sales for the six months ended June 30, 2026 from 22.2% of net sales for the six months ended June 30, 2025, primarily driven by increased selling, general and administrative costs, partially offset by $12.3 million reduction in cost of sales as a result of tariff refunds.
For the six months ended June 30, 2026, operating income in the Zig-Zag products segment decreased $11.7 million, or 36.9% compared to the prior year period. Operating income as a percentage of net sales decreased to 27.7% of net sales for the six months ended June 30, 2026 from 33.6% of net sales for the six months ended June 30, 2025, primarily driven by an increase in sales and marketing costs offset by improved margins on product mix and $2.4 million reduction in cost of sales as a result of tariff refunds.
For the six months ended June 30, 2026, operating income in the Stoker’s products segment decreased $4.5 million, or 8.3% compared to the prior year period. Operating income as a percentage of net sales decreased to 25.5% of net sales for the six months ended June 30, 2026 from 42.1% of net sales for the six months ended June 30, 2025, primarily driven by higher sales and marketing costs, margin contribution of modern oral products offset by $9.9 million reduction in cost of sales as a result of tariff refunds.
Included in consolidated operating income are costs of the Company which are not assigned to one of the two reportable segments and include: (i) corporate overhead expense, including executive management, finance, legal and information technology salaries, and professional services, such as audit, external legal costs and information technology services, as well as (ii) costs related to the FDA premarket tobacco product application. For the six months ended June 30, 2026, unallocated costs were $40.5 million compared to $36.4 million in the prior year period, an increase of $4.1 million or 11.3%, primarily driven by joint venture related corporate expenses.
Other Expense, net: For the six months ended June 30, 2026, other expense increased $0.1 million compared to the prior year period due to an honorarium gift in the current year period that was not made in the prior year period.
Interest Expense, net: For the six months ended June 30, 2026, interest expense, net decreased $0.9 million or 9.2% due to an increase in interest income as a result of interest of $0.6 million received on the tariff refund.
Investment Loss (Gain): For the six months ended June 30, 2026, investment loss was $0.9 million compared to investment income of $0.5 million in the prior-year period, primarily due to higher realized loss from a non-cash valuation adjustment during the period.
Income From Equity Method Investments: For the six months ended June 30, 2026, income from investments in equity securities increased $5.9 million compared to the prior year period as a result of GWO.
Loss on Extinguishment of Debt: There was no loss on extinguishment of debt for the six months ended June 30, 2026. Loss on extinguishment of debt for the six months ended June 30, 2025 was $1.2 million as a result of the redemption of the 2026 Notes in February 2025.
Income Tax (Benefit) Expense: Our income tax expense of $0.9 million was 3.5% of income before income taxes for the six months ended June 30, 2026. Our effective income tax rate was 16.1% for the six months ended June 30, 2025. The change in tax rate is primarily attributable to the release of a valuation allowance on deferred tax assets in the current year period.
Net Income Attributable to Non-Controlling Interest: Net income attributable to non-controlling interest was $9.0 million and $3.9 million, respectively, for the six months ended June 30, 2026 and 2025. The increase in non-controlling interest compared to the prior year period is primarily due to higher sales volumes and improved net income of our joint venture as well as tariff refunds related to products sold through our joint venture company.
Net Income Attributable to Turning Point Brands, Inc.: Due to the factors described above, net income attributable to Turning Point Brands, Inc. for the six months ended June 30, 2026 and 2025, was $15.3 million and $28.9 million, respectively.
EBITDA and Adjusted EBITDA
To supplement our financial information presented in accordance with generally accepted accounting principles in the United States, or U.S. GAAP, we use non-U.S. GAAP financial measures including EBITDA and Adjusted EBITDA. We believe Adjusted EBITDA provides useful information to management and investors regarding certain financial and business trends relating to our financial condition and results of operations. Adjusted EBITDA is used by management to compare our performance to that of prior periods for trend analyses and planning purposes and is presented to our Board of Directors. We believe that EBITDA and Adjusted EBITDA are appropriate measures of operating performance because they eliminate the impact of expenses that do not relate to operating performance. In addition, our debt instruments contain covenants which use Adjusted EBITDA calculations.
We define “EBITDA” as net income attributable to Turning Point Brands, Inc. before interest expense, gain (loss) on extinguishment of debt, income tax expense, depreciation and amortization. We define “Adjusted EBITDA” as net income before interest expense, gain (loss) on extinguishment of debt, income tax expense, depreciation, amortization, other non-cash items and other items we do not consider the ordinary course in our evaluation of ongoing operating performance noted in the reconciliation below. Among other items that we adjust Adjusted EBITDA for is FDA PMTA expense. The Company believes it is appropriate to adjust for this spend as the costs are incurred in connection with what we view as a non-traditional regulatory process that requires applications be submitted for covered products that are already on the market. As a result, Company’s management believes it is most appropriate to assess the performance of the Company’s business – the sale of our various products - without regard to these costs and believes that adjusting for these costs provides investors and the public markets with the most meaningful metrics to assess performance of the business. The Company reconciles its EBITDA metrics to Net income attributable to Turning Point Brands, Inc. because that measure reflects the Company’s portion of the profitability from consolidated joint ventures after removing results attributable to our partners in such joint ventures.
Non-U.S. GAAP measures should not be considered a substitute for, or superior to, financial measures calculated in accordance with U.S. GAAP. Adjusted EBITDA excludes significant expenses required to be recorded in our financial statements by U.S. GAAP and is subject to inherent limitations. Other companies in our industry may calculate this non-U.S. GAAP measure differently than we do or may not calculate it at all, limiting its usefulness as a comparative measure. The tables below provide reconciliations between net income and Adjusted EBITDA.
| Three Months Ended |
Six Months Ended |
|||||||||||||||
| (in thousands) |
June 30, |
June 30, |
||||||||||||||
| 2026 |
2025 |
2026 |
2025 |
|||||||||||||
| Net income attributable to Turning Point Brands, Inc. |
$ | 3,598 | $ | 14,480 | $ | 15,265 | $ | 28,875 | ||||||||
| Add: |
||||||||||||||||
| Interest expense, net |
4,388 | 5,140 | 8,957 | 9,541 | ||||||||||||
| Loss on extinguishment of debt |
- | - | - | 1,235 | ||||||||||||
| Income tax expense |
3,974 | 4,244 | 1,482 | 6,284 | ||||||||||||
| Depreciation expense |
939 | 842 | 1,733 | 1,670 | ||||||||||||
| Amortization expense |
1,429 | 1,048 | 2,714 | 1,870 | ||||||||||||
| EBITDA |
$ | 14,328 | $ | 25,754 | $ | 30,151 | $ | 49,475 | ||||||||
| Components of Adjusted EBITDA |
||||||||||||||||
| Corporate restructuring (a) |
133 | - | 231 | - | ||||||||||||
| Stock based compensation (b) |
2,701 | 1,628 | 5,639 | 3,292 | ||||||||||||
| Transactional expenses and strategic initiatives (c) |
94 | 569 | 239 | 746 | ||||||||||||
| Non-recurring legal (d) |
667 | 504 | 820 | 504 | ||||||||||||
| FDA PMTA (e) |
3,170 | 1,651 | 3,460 | 3,242 | ||||||||||||
| Mark-to-market loss (gain) on Canadian inter-company note (f) |
598 | (665 | ) | 481 | (350 | ) | ||||||||||
| Tariff adjustment (g) |
(8,475 | ) | - | (2,572 | ) | - | ||||||||||
| Manufacturing start-up costs (h) |
657 | - | 1,251 | - | ||||||||||||
| Honorarium (i) |
63 | - | 126 | - | ||||||||||||
| Non-cash asset impairment (j) |
1,307 | 908 | 1,307 | 908 | ||||||||||||
| Gain on investment (k) |
- | (714 | ) | - | (714 | ) | ||||||||||
| Non-recurring freight (l) |
- | 837 | - | 837 | ||||||||||||
| ERP/CRM (m) |
- | - | - | 211 | ||||||||||||
| Adjusted EBITDA |
$ | 15,243 | $ | 30,472 | $ | 41,133 | $ | 58,151 | ||||||||
| (a) |
Represents costs associated with corporate restructuring, including severance and early retirement. |
| (b) |
Represents non-cash stock options, restricted stock, PRSUs, etc. |
| (c) |
Represents the fees incurred for transaction expenses. |
| (d) |
Represents legal expenses incurred in connection with litigation related to an insurance claim. |
| (e) | Represents costs associated with applications related to FDA premarket tobacco product application (“PMTA”). The PMTA regime requires the Company to submit an application to the FDA to receive marketing authorization to continue to sell certain of its product lines with continued sales permitted during the pendency of the applications. The application is a one-time resource-intensive process for each covered product line; however, due to the nature of the implementation process for those product lines already in the market, applications can take multiple years to complete rather than the typical one-time submission. The Company has only two product lines currently subject to the PMTA process, having utilized other regulatory pathway options available for our other product lines. The Company does not expect to submit additional PMTA applications for any new product lines after the submission for the remaining two are complete. |
| (f) | Represents a mark-to-market gain attributable to foreign exchange fluctuation. |
| (g) |
Represents adjustment to current period costs of goods sold to exclude tariffs subject to refund or refunded. |
| (h) | Represents non-recurring expenses incurred during the start-up of manufacturing lines. |
| (i) | Represents an honorarium gift included in other expense, net. |
| (j) | Represents impairment of investment assets. |
| (k) | Represents gain on investments. |
| (l) | Represents elevated non-recurring outbound freight costs due to ERP transition. |
| (m) | Represents costs associated with scoping and mobilization of new ERP and CRM systems and cost of duplicative ERP licenses. |
Liquidity and Capital Resources
As of June 30, 2026, we have $268.3 million of cash on hand and $70.7 million of availability under the 2023 ABL Facility. We have no borrowings outstanding under our 2023 ABL Facility as of June 30, 2026. Our principal uses for cash are working capital, debt service, and capital expenditures.
Our adjusted working capital, which we define as current assets less cash and current liabilities, increased $24.2 million compared to the prior year end. The increase in working capital is primarily the result of a $25.4 million increase in inventory and a $15.0 million increase in other current assets, partially offset by a decrease of $3.0 million in accounts receivable, an increase of $14.9 million in accounts payable and a $1.7 million decrease in accrued liabilities. With our strong cash balance, free cash flow generation and borrowing availability under the 2023 ABL Facility, we expect to have ample liquidity to satisfy our operating cash requirements for the foreseeable future.
| June 30, |
December 31, |
|||||||
| (in thousands) |
2026 |
2025 |
||||||
| Current assets |
$ | 231,827 | $ | 194,390 | ||||
| Current liabilities |
88,216 | 75,007 | ||||||
| Adjusted working capital |
$ | 143,611 | $ | 119,383 | ||||
Cash Flows from Continuing Operations
Our cash flows from continuing operations as reflected in the Consolidated Statements of Cash Flows are summarized as follows:
| (in thousands) |
Six Months Ended |
|||||||
| June 30, |
||||||||
| Cash provided by (used in): |
2026 |
2025 |
||||||
| Operating activities |
$ | 4,068 | $ | 29,230 | ||||
| Investing activities |
$ | (11,595 | ) | $ | (8,626 | ) | ||
| Financing activities |
$ | 52,759 | $ | 40,312 | ||||
Cash Flows from Operating Activities
For the six months ended June 30, 2026, net cash provided by operating activities was $4.1 million, a decrease of $25.2 million compared to the prior year period. The decrease is primarily due to $14.0 million in working capital, decrease in net income, net of non-cash items of $15.2 million, and partially offset by, $4.0 million in other assets. The primary drivers of non-cash items were a $3.1 million increase in deferred tax benefit, a $5.9 million increase in income from equity method investment, $1.2 million increase in gain on investments, $2.3 million increase in stock compensation expense and a $1.2 million decrease in loss on extinguishment of debt compared to the prior year period. The decrease in cash from working capital compared to the prior year period was primarily driven by the timing of payments.
Cash Flows used Investing Activities
For the six months ended June 30, 2026, net cash used in investing activities was $11.6 million, an increase of $3.0 million due to payment on an option agreement of $4.9 million partially offset by a reduction in capital expenditures and payments for equity investments.
Cash Flows from Financing Activities
For the six months ended June 30, 2026, net cash provided by financing activities was $52.8 million, an increase of $12.4 million compared to the prior year period, primarily due to an increase of equity offering proceeds of $59.6 million, offset by to a net decrease in cash of $42.7 million related to the February 2025 issuance of the 2032 Notes, $2.5 million decrease for tax distributions, and $1.3 million related to stock compensation activity.
Dividends, Share Issuances, and Shares Repurchases
A dividend of $0.08 per common share was paid on July 10, 2026, to shareholders of record at the close of business on June 19, 2026.
On February 25, 2020, our Board of Directors approved a $50.0 million share repurchase program, which is intended for opportunistic execution based upon a variety of factors including market dynamics. The program is subject to the ongoing discretion of the Board of Directors. On October 25, 2021, the Board of Directors increased the approved share repurchase program by $30.7 million, and by $24.6 million on February 24, 2022. On November 6, 2024, the Company's Board of Directors increased the Company’s share repurchase authorization by $77.9 million to an aggregate amount of $100.0 million. On November 4, 2025, the Company's Board of Directors increased the share repurchase authorization by $100.0 million to an aggregate amount of $200.0 million. For the six months ended June 30, 2026, there were no repurchases under the share repurchase program. As of June 30, 2026, there was $200.0 million in remaining repurchase authority under the plan.
The Company entered into an at-the-market offering program (the "ATM Program") on December 13, 2024, with B. Riley Securities Inc. and Barclays Capital Inc. During the quarter ended June 30, 2026, the Company sold 672,884 shares of our Common Stock under the ATM Program at an average selling price of $90.30 per share for gross proceeds of $60.8 million, less underwriter's commission and expenses of approximately $1.2 million, for net proceeds of $59.6 million. The shares were issued from repurchased common stock on a first in first out basis. The Company recorded the gain, corresponding to the difference in between the reacquisition cost of treasury stock and the value of treasury stock reissued, into APIC within the Consolidated Statements of Changes in Stockholders' Equity. As of June 30, 2026, there was $139.2 million of capacity remaining under the ATM Program.
Long-Term Debt
Notes payable and long-term debt consisted of the following at June 30, 2026 and December 31, 2025, in order of preference:
| June 30, |
December 31, |
|||||||
| 2026 |
2025 |
|||||||
| 2032 Notes |
$ | 300,000 | $ | 300,000 | ||||
| Less deferred financing costs |
(5,855 | ) | (6,375 | ) | ||||
| Notes payable and long-term debt |
$ | 294,145 | $ | 293,625 |
|
|||
2032 Notes
In February 2025, the Company closed a private offering of $300.0 million aggregate principal amount of 7.625% senior secured notes due to mature on March 15, 2032 (the “2032 Notes”). Interest on the 2032 Notes is payable semi-annually on March 15 and September 15 of each year, commencing on September 15, 2025. We used the proceeds from the offering (i) to repay all obligations under and redeem all of our 5.625% senior secured notes due 2026 (the "2026 Notes), (ii) to pay related fees, costs and expenses and (iii) for general corporate purposes. The 2032 Notes are fully and unconditionally guaranteed on a senior secured basis, jointly and severally, by each current and future wholly-owned domestic restricted subsidiary of the Company that guaranteed the 2026 Notes (collectively, the “Guarantors” as defined in the indenture governing the 2032 Notes or the “2032 Notes Indenture”). The 2032 Notes and the related guarantees are secured by first-priority liens on substantially all of the assets of the Company and the Guarantors, subject to certain exceptions. Proceeds from the offering were approximately $293.0 million.
The 2032 Notes Indenture contains covenants that, among other things, restrict the ability of the Company and its restricted subsidiaries to: (i) grant or incur liens; (ii) incur, assume or guarantee additional indebtedness; (iii) sell or otherwise dispose of assets, including capital stock of subsidiaries; (iv) make certain investments; (v) pay dividends, make distributions or redeem or repurchase capital stock; (vi) engage in certain transactions with affiliates; and (vii) consolidate or merge with or into, or sell substantially all of our assets to another entity. These covenants are subject to several limitations and exceptions set forth in the 2032 Notes Indenture. For instance, the Company is generally permitted to make restricted payments, including the payment of dividends to shareholders, provided that, at the time of payment, or as a result of payment, the Company is not in default on its debt covenants; however, there are earnings and market capitalization requirements that if not met could limit the aggregate amount of quarterly dividends payable during a fiscal year. The 2032 Notes Indenture provides for customary events of default. The Company was in compliance with all covenants under the 2032 Notes as of June 30, 2026.
We incurred debt issuance costs attributable to the 2032 Notes of $7.3 million which are amortized to interest expense using the straight-line method over the expected life of the 2032 Notes.
2023 ABL Facility
On November 7, 2023, TPB Specialty Finance, LLC, a wholly-owned subsidiary of the Company (the “ABL Borrower”), entered into a new $75.0 million asset-backed revolving credit facility (the “2023 ABL Facility”), with the several lenders thereunder, and Barclays Bank Plc, as administrative agent (the “Administrative Agent”) and as collateral agent and First-Citizens Bank & Trust Company as additional collateral agent (the “Additional Collateral Agent”). Under the 2023 ABL Facility, the ABL Borrower may draw up to $75.0 million under Revolving Credit Loans and Last In Last Out (“LILO”) Loans. The 2023 ABL Facility includes a $40.0 million accordion feature. In connection with the 2023 ABL Facility, Turning Point Brands contributed certain existing inventory to the ABL Borrower. The 2023 ABL Facility is secured on a first priority basis (subject to customary exceptions) by all assets of the ABL Borrower.
The 2023 ABL Facility contains customary borrowing conditions including a borrowing base equal to the sum of (a) the lesser of (1) 85% of the lower of (A) the market value (on a first in first out basis) of the sum of eligible inventory, plus eligible in-transit inventory of the ABL Borrower and (B) 85% of the cost of the sum of eligible inventory, plus eligible in-transit inventory of the ABL Borrower and (2) 85% of the net orderly liquidation value (“NOLV”) percentage of the lower of (1)(A) or (1)(B); plus (b) 85% of the face value of all eligible accounts of the ABL Borrower minus (c) the amount of all eligible reserves. The 2023 ABL Facility also includes a LILO borrowing base equal to the sum of (a) the lesser of: (1) 10% of the lower of (A) the market value (on a first in first out basis) of the sum of eligible inventory, plus eligible in-transit inventory of the ABL Borrower and (B) the cost of the sum of eligible inventory, plus eligible in-transit inventory and (2) 10% of the NOLV percentage of the lower of (1)(A) or (1)(B); plus (b) 10% of the face amount of eligible account; minus (c) the amount of all eligible reserves.
Amounts borrowed under the 2023 ABL Facility are subject to an interest rate margin per annum equal to (a) from and after the closing date until the last day of the first full fiscal quarter ended after the closing date, (i) 1.25% per annum, in the case base rate loans, and (ii) 2.25% per annum, in the case of revolving credit loans that are secured overnight financing rate (“SOFR”) loans, (b)(i) 2.25% per annum, in the case of LILO loans that are base rate loans, and (ii) 3.25% per annum, in the case of LILO loans that are SOFR loans, (c) on the first day of each fiscal quarter, the applicable interest rate margins will be determined from the pricing grid below based upon the historical excess availability for the most recent fiscal quarter ended immediately prior to the relevant date, as calculated by the Administrative Agent.
| Applicable Margin |
Applicable Margin |
||||||
| Level |
Historical Excess Availability |
for SOFR Loans |
for Base Rate Loans |
||||
| I |
Greater than or equal to 66.66% |
1.75% | 0.75% | ||||
| II |
Less than 66.66%, but greater than or equal to 33.33% |
2.00% | 1.00% | ||||
| III |
Less than 33.33% |
2.25% | 1.25% |
The 2023 ABL Facility also requires the Company and its restricted subsidiaries to maintain a fixed charge coverage ratio of at least 1.00 to 1.00 as of the end of any four consecutive fiscal quarters if excess availability is less than the greater of (a) 12.5% of the line cap and (b) $9.4 million, at any time and continuing until excess availability is equal to or exceeds the greater of (i) 12.5% of the line and (ii) $9.4 million for thirty (30) consecutive calendar days with the $9.4 million level automatically increased in proportion to the amount of any increase in the aggregate revolving credit commitments thereunder in connection with any incremental facility.
The 2023 ABL Facility will mature on the earlier of (x) November 7, 2027 and (y) the date that is 91 days prior to the maturity date of any material debt of the ABL Borrower or the Company or any of its restricted subsidiaries (subject to customary extensions agreed by the lenders thereunder); provided that clause (y) will not apply to the extent that on any applicable date of determination (on any date prior to the date set forth in clause (y)), (A) the sum of (x) cash that is held in escrow for the repayment of such material debt pursuant to arrangements satisfactory to the Administrative Agent, (y) cash that is held in accounts with the Administrative Agent and/or the Additional Collateral Agent, plus (z) excess availability, is sufficient to repay such material debt and (B) the ABL Borrower has excess availability of at least $15.0 million after giving effect to such repayment of material debt, including any borrowings under the commitments in connection therewith.
The Company has not drawn any borrowings under the 2023 ABL Facility but has letters of credit of approximately $2.3 million outstanding under the facility and has an available borrowing base of $70.7 million based on the borrowing base as of June 30, 2026.
The Company incurred debt issuance costs attributable to the 2023 ABL Facility of $2.6 million which are amortized to interest expense using the straight-line method over the expected life of the 2023 ABL Facility.
Additional Information with Respect to Unrestricted Subsidiaries
Under the terms of the 2032 Notes, and the 2026 Notes that were redeemed with proceeds from the February 2025 issuance of the 2032 Notes, the Company designated certain of its subsidiaries as “Unrestricted Subsidiaries”, including Interchange Partners LLC and Intrepid Brands, LLC. The Company is required under the terms of the indenture governing the 2032 Notes to present additional information that reflects the financial condition and results of operations of the Company and its Restricted Subsidiaries separate from the financial condition and results of operations of the Company’s Unrestricted Subsidiaries as of and for the periods presented. This additional information is presented below.
Income Statements for the three and six months ended June 30, 2026 and 2025 (unaudited):
| Three Months Ended June 30, |
||||||||||||||||||||||||
| 2026 |
2025 |
|||||||||||||||||||||||
| Company and |
Company and |
|||||||||||||||||||||||
| Restricted |
Unrestricted |
Restricted |
Unrestricted |
|||||||||||||||||||||
| Subsidiaries |
Subsidiaries |
Consolidated |
Subsidiaries |
Subsidiaries |
Consolidated |
|||||||||||||||||||
| Net sales |
$ | 90,185 | $ | 52,775 | $ | 142,960 | $ | 99,905 | $ | 16,729 | $ | 116,634 | ||||||||||||
| Cost of sales |
27,444 | 21,812 | 49,256 | 43,468 | 6,543 | 50,011 | ||||||||||||||||||
| Gross profit |
62,741 | 30,963 | 93,704 | 56,437 | 10,186 | 66,623 | ||||||||||||||||||
| Selling, general, and administrative expenses |
53,565 | 23,426 | 76,991 | 35,236 | 5,060 | 40,296 | ||||||||||||||||||
| Other operating income |
- | - | - | - | - | - | ||||||||||||||||||
| Operating income |
9,176 | 7,537 | 16,713 | 21,201 | 5,126 | 26,327 | ||||||||||||||||||
| Other expense, net |
- | 63 | 63 | - | - | - | ||||||||||||||||||
| Interest expense (income), net |
4,636 | (385 | ) | 4,251 | 5,493 | (353 | ) | 5,140 | ||||||||||||||||
| Investment (gain) loss |
1,155 | (66 | ) | 1,089 | (105 | ) | 27 | (78 | ) | |||||||||||||||
| (Income) loss from equity method investment |
(2,627 | ) | (47 | ) | (2,674 | ) | - | 61 | 61 | |||||||||||||||
| Income before income taxes |
6,012 | 7,972 | 13,984 | 15,813 | 5,391 | 21,204 | ||||||||||||||||||
| Income tax (benefit) expense |
1,586 | 2,097 | 3,683 | 3,165 | 1,079 | 4,244 | ||||||||||||||||||
| Consolidated net income |
4,426 | 5,875 | 10,301 | 12,648 | 4,312 | 16,960 | ||||||||||||||||||
| Net income (loss) attributable to non-controlling interest |
2,989 | 3,714 | 6,703 | 64 | 2,416 | 2,480 | ||||||||||||||||||
| Net income attributable to Turning Point Brands, Inc. |
$ | 1,437 | $ | 2,161 | $ | 3,598 | $ | 12,584 | $ | 1,896 | $ | 14,480 | ||||||||||||
| Six Months Ended June 30, |
||||||||||||||||||||||||
| 2026 |
2025 |
|||||||||||||||||||||||
| Company and |
Company and |
|||||||||||||||||||||||
| Restricted |
Unrestricted |
Restricted |
Unrestricted |
|||||||||||||||||||||
| Subsidiaries |
Subsidiaries |
Consolidated |
Subsidiaries |
Subsidiaries |
Consolidated |
|||||||||||||||||||
| Net sales |
$ | 178,216 | $ | 89,022 | $ | 267,238 | $ | 192,231 | $ | 30,839 | $ | 223,070 | ||||||||||||
| Cost of sales |
68,788 | 36,451 | 105,239 | 84,309 | 12,528 | 96,837 | ||||||||||||||||||
| Gross profit (loss) |
109,428 | 52,571 | 161,999 | 107,922 | 18,311 | 126,233 | ||||||||||||||||||
| Selling, general, and administrative expenses |
92,627 | 40,175 | 132,802 | 67,270 | 9,447 | 76,717 | ||||||||||||||||||
| Operating income |
16,801 | 12,396 | 29,197 | 40,652 | 8,864 | 49,516 | ||||||||||||||||||
| Other (income) expense, net |
- | 126 | 126 | - | - | - | ||||||||||||||||||
| Interest expense (income), net |
9,483 | (809 | ) | 8,674 | 10,096 | (542 | ) | 9,554 | ||||||||||||||||
| Investment (gain) loss |
881 | 57 | 938 | (345 | ) | (174 | ) | (519 | ) | |||||||||||||||
| (Income) loss from equity method investment |
(5,478 | ) | (179 | ) | (5,657 | ) | - | 211 | 211 | |||||||||||||||
| Loss on extinguishment of debt |
- | - | - | 1,235 | - | 1,235 | ||||||||||||||||||
| Income before income taxes |
11,915 | 13,201 | 25,116 | 29,666 | 9,369 | 39,035 | ||||||||||||||||||
| Income tax expense |
411 | 462 | 873 | 4,776 | 1,508 | 6,284 | ||||||||||||||||||
| Consolidated net income |
11,504 | 12,739 | 24,243 | 24,890 | 7,861 | 32,751 | ||||||||||||||||||
| Net (loss) income attributable to non-controlling interest |
2,917 | 6,061 | 8,978 | (257 | ) | 4,133 | 3,876 | |||||||||||||||||
| Net income attributable to Turning Point Brands, Inc. |
$ | 8,587 | $ | 6,678 | $ | 15,265 | $ | 25,147 | $ | 3,728 | $ | 28,875 | ||||||||||||
Balance Sheet as of June 30, 2026 (unaudited):
| Company and |
||||||||||||||||
| Restricted |
Unrestricted |
|||||||||||||||
| Subsidiaries |
Subsidiaries |
Eliminations |
Consolidated |
|||||||||||||
| ASSETS |
||||||||||||||||
| Current assets: |
||||||||||||||||
| Cash |
$ | 222,727 | $ | 45,580 | $ | - | $ | 268,307 | ||||||||
| Accounts receivable, net |
17,312 | 5,386 | - | 22,698 | ||||||||||||
| Inventories |
123,591 | 9,843 | - | 133,434 | ||||||||||||
| Other current assets |
67,989 | 7,706 | - | 75,695 | ||||||||||||
| Total current assets |
431,619 | 68,515 | - | 500,134 | ||||||||||||
| Property, plant, and equipment, net |
39,455 | 248 | - | 39,703 | ||||||||||||
| Right of use assets |
15,689 | - | - | 15,689 | ||||||||||||
| Deferred financing costs, net |
858 | - | - | 858 | ||||||||||||
| Goodwill |
135,830 | - | - | 135,830 | ||||||||||||
| Other intangible assets, net |
63,419 | - | - | 63,419 | ||||||||||||
| Master Settlement Agreement (MSA) escrow deposits |
29,684 | - | - | 29,684 | ||||||||||||
| Other assets |
53,631 | 16,248 | - | 69,879 | ||||||||||||
| Investment in unrestricted subsidiaries |
- | 14,630 | (14,630 | ) | - | |||||||||||
| Total assets |
$ | 770,185 | $ | 99,641 | $ | (14,630 | ) | $ | 855,196 | |||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY |
||||||||||||||||
| Current liabilities: |
||||||||||||||||
| Accounts payable |
$ | 23,652 | $ | 11,640 | $ | - | $ | 35,292 | ||||||||
| Accrued liabilities |
9,577 | 43,347 | - | 52,924 | ||||||||||||
| Total current liabilities |
33,229 | 54,987 | - | 88,216 | ||||||||||||
| Deferred tax liabilities, net |
7,851 | - | - | 7,851 | ||||||||||||
| Notes payable and long-term debt |
294,145 | - | - | 294,145 | ||||||||||||
| Other long-term liabilities |
- | - | - | - | ||||||||||||
| Lease liabilities |
10,960 | - | - | 10,960 | ||||||||||||
| Total liabilities |
346,185 | 54,987 | - | 401,172 | ||||||||||||
| Commitments and contingencies |
||||||||||||||||
| Stockholders’ equity: |
||||||||||||||||
| Total Turning Point Brands, Inc. Stockholders’ Equity/Net parent investment in unrestricted subsidiaries |
419,952 | 24,776 | (14,630 | ) | 430,098 | |||||||||||
| Non-controlling interest |
4,048 | 19,878 | - | 23,926 | ||||||||||||
| Total stockholders’ equity |
424,000 | 44,654 | (14,630 | ) | 454,024 | |||||||||||
| Total liabilities and stockholders’ equity |
$ | 770,185 | $ | 99,641 | $ | (14,630 | ) | $ | 855,196 | |||||||
Balance Sheet as of December 31, 2025:
| Company and |
||||||||||||||||
| Restricted |
Unrestricted |
|||||||||||||||
| Subsidiaries |
Subsidiaries |
Eliminations |
Consolidated |
|||||||||||||
| ASSETS |
||||||||||||||||
| Current assets: |
||||||||||||||||
| Cash |
$ | 179,344 | $ | 43,416 | $ | - | $ | 222,760 | ||||||||
| Accounts receivable, net |
23,335 | 2,391 | - | 25,726 | ||||||||||||
| Inventories, net |
103,408 | 4,581 | - | 107,989 | ||||||||||||
| Other current assets |
55,515 | 5,160 | - | 60,675 | ||||||||||||
| Total current assets |
361,602 | 55,548 | - | 417,150 | ||||||||||||
| Property, plant, and equipment, net |
36,107 | 140 | - | 36,247 | ||||||||||||
| Right of use assets |
14,480 | - | - | 14,480 | ||||||||||||
| Deferred financing costs, net |
1,180 | - | - | 1,180 | ||||||||||||
| Goodwill |
136,097 | - | - | 136,097 | ||||||||||||
| Other intangible assets, net |
64,042 | - | - | 64,042 | ||||||||||||
| Master Settlement Agreement (MSA) escrow deposits |
29,887 | - | - | 29,887 | ||||||||||||
| Other assets |
48,810 | 15,857 | - | 64,667 | ||||||||||||
| Investment in unrestricted subsidiaries |
- | 11,069 | (11,069 | ) | - | |||||||||||
| Total assets |
$ | 692,205 | $ | 82,614 | $ | (11,069 | ) | $ | 763,750 | |||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY |
||||||||||||||||
| Current liabilities: |
||||||||||||||||
| Accounts payable |
$ | 11,857 | $ | 8,563 | $ | - | $ | 20,420 | ||||||||
| Accrued liabilities |
10,651 | 43,936 | - | 54,587 | ||||||||||||
| Total current liabilities |
22,508 | 52,499 | - | 75,007 | ||||||||||||
| Deferred tax liabilities, net |
8,289 | - | - | 8,289 | ||||||||||||
| Notes payable and long-term debt |
293,625 | - | - | 293,625 | ||||||||||||
| Other long-term liabilities |
4,138 | - | - | 4,138 | ||||||||||||
| Lease liabilities |
10,708 | - | - | 10,708 | ||||||||||||
| Total liabilities |
339,268 | 52,499 | - | 391,767 | ||||||||||||
| Commitments and contingencies |
||||||||||||||||
| Stockholders’ equity: |
||||||||||||||||
| Total Turning Point Brands, Inc. Stockholders’ Equity/Net parent investment in unrestricted subsidiaries |
351,576 | 13,797 | (11,069 | ) | 354,304 | |||||||||||
| Non-controlling interest |
1,361 | 16,318 | - | 17,679 | ||||||||||||
| Total stockholders’ equity |
352,937 | 30,115 | (11,069 | ) | 371,983 | |||||||||||
| Total liabilities and stockholders’ equity |
$ | 692,205 | $ | 82,614 | $ | (11,069 | ) | $ | 763,750 | |||||||
Off-balance Sheet Arrangements
At June 30, 2026 and December 31, 2025 we had no foreign currency contracts outstanding.
Inflation
Inflation has a substantial negative effect on the purchasing power of consumers. While historically, we have been able to increase prices at a rate equal to or greater than that of inflation, doing so could be difficult in an inflationary environment. However, we have implemented price increases in areas where doing so has been feasible. In addition, we have been able to maintain a relatively stable variable cost structure for our products due, in part, to our existing contractual agreements for the purchases of tobacco and our premium cigarette rolling papers.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
Foreign Currency Sensitivity
During the three months ended June 30, 2026, there have been no material changes in our exposure to exchange rate fluctuation risk, as reported within our 2025 Annual Report on Form 10-K. Please refer to our ‘Quantitative and Qualitative Disclosures about Market Risk’ included in our 2025 Annual Report on Form 10-K filed with the SEC.
Credit Risk
During the six months ended June 30, 2026, there have been no material changes in our exposure to credit risk, as reported within our 2025 Annual Report on Form 10-K. Please refer to our ‘Quantitative and Qualitative Disclosures about Market Risk’ included in our 2025 Annual Report on Form 10-K filed with the SEC.
Interest Rate Sensitivity
In February 2025, we issued the 2032 Notes in an aggregate principal amount of $300.0 million. We carry the 2032 Notes at face value. Since the 2032 Notes bear interest at a fixed rate, we have no financial statement risk associated with changes in interest rates. Our remaining debt instrument is the 2023 ABL Facility, which as of June 30, 2026 and the filing date of this report had no borrowings outstanding.
Item 4. Controls and Procedures
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Act. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our consolidated financial statements for external reporting purposes in accordance with GAAP. Our internal control over financial reporting includes policies and procedures that: (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with GAAP; (3) provide reasonable assurance that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and (4) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the consolidated financial statements. Our management, with the participation of our CEO and CFO, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e)) as of June 30, 2026. Based on this evaluation, our CEO and CFO concluded that our disclosure controls and procedures were effective as of that date.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Changes in Internal Controls over Financial Reporting
There were no changes in the Company’s internal controls over financial reporting during the quarter ended June 30, 2026 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
PART II—OTHER INFORMATION
See “Risk Factors—We are subject to significant product liability litigation” in our 2025 Annual Report on Form 10-K for additional details.
In addition to the other information set forth in this report, carefully consider the factors discussed in the ‘Risk Factors’ section contained in our 2025 Annual Report on Form 10-K. There have been no material changes to the Risk Factors set forth in the 2025 Annual Report on Form 10-K.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
On February 25, 2020, the Company’s Board of Directors approved a $50.0 million share repurchase program, which is intended for opportunistic execution based upon a variety of factors including market dynamics. On October 25, 2021, the Board of Directors increased the approved share repurchase program by $30.7 million, and by an additional $24.6 million on February 24, 2022. On November 6, 2024, the Company's Board of Directors increased the Company’s share repurchase authorization by $77.9 million to an aggregate amount of $100.0 million. On November 4, 2025, the Company's Board of Directors increased the share repurchase authorization by $100.0 million to an aggregate amount of $200.0 million. As of June 30, 2026 there remains $200.0 million in authority to repurchase shares under the plan. This share repurchase program has no expiration date and is subject to the ongoing discretion of the Board of Directors. All repurchases to date under our stock repurchase programs have been made through open market transactions, but in the future, we may also purchase shares through privately negotiated transactions or 10b5-1 repurchase plans.
There were no purchases of our common stock made by us during the three months ended June 30, 2026 in connection with the repurchase program described above.
Item 3. Defaults Upon Senior Securities
Not applicable.
Item 4. Mine Safety Disclosures
Not applicable.
applicable.
| Exhibit No. |
Description |
| Rule 13a-14(a)/15d-14(a) Certification of Graham Purdy.* |
|
| Rule 13a-14(a)/15d-14(a) Certification of Andrew Flynn.* |
|
| Rule 13a-14(a)/15d-14(a) Certification of Brian Wigginton.* |
|
| Section 1350 Certifications pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.* |
|
| 101 |
XBRL (eXtensible Business Reporting Language). The following materials from Turning Point Brands, Inc.’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed on August 4, 2026, formatted in Inline XBRL (iXBRL): (i) consolidated balance sheets, (ii) consolidated statements of income, (iii) consolidated statements of comprehensive income, (iv) consolidated statements of cash flows, and (v) the notes to consolidated financial statements.* |
| 104 |
Cover Page Interactive Data File (formatted in iXBRL and included in Exhibit 101).* |
| * |
Filed or furnished herewith |
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| TURNING POINT BRANDS, INC. |
|||
| By: /s/ Graham Purdy |
|||
| Name: |
Graham Purdy |
||
| Title: President and Chief Executive Officer |
|||
| By: /s/ Andrew Flynn |
|||
| Name: |
Andrew Flynn |
||
| Title: Chief Financial Officer |
|||
| By: /s/ Brian Wigginton |
|||
| Name: |
Brian Wigginton |
||
| Title: Chief Accounting Officer |
| Date: August 4, 2026 |